Chapter 124

REFERENCES

1. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila). 2009;47:911-1084.

2. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122:S829-S861.

3. Roy TM, Ossorio MA, Cipolla LM, et al. Pulmonary complica-tions after tricyclic antidepressant overdose. Chest. 1989;96: 852-856.

4. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344:665-671.

5. Ovsyshcher IE, Barold SS. Drug induced bradycardia: to pace or not to pace? Pacing Clin Electrophysiol. 2004;27:1144-1147.

6. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 8: advanced challenges in resuscitation: section 2: toxicology in ECC. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000;102:I223-I228.

7. Chen JY, Liu PY, Chen JH, et al. Safety of transvenous tempo-rary cardiac pacing in patients with accidental digoxin overdose and symptomatic bradycardia. Cardiology. 2004;102:152-155.

8. Teba L, Schiebel F, Dedhia HV, et al. Beneficial effect of norepi-nephrine in the treatment of circulatory shock caused by tricy-clic antidepressant overdose. Am J Emerg Med. 1988;6:566-568.

9. Vernon DD, Banner W Jr, Garrett JS, et al. Efficacy of dopamine and norepinephrine for treatment of hemodynamic compro-mise in amitriptyline intoxication. Crit Care Med. 1991;19: 544-549.

10. Buchman AL, Dauer J, Geiderman J. The use of vasoac-tive agents in the treatment of refractory hypotension seen in tricyclic antidepressant overdose. J Clin Psychopharmacol. 1990;10:409-413.

11. Rangel C, Shu RG, Lazar LD, et al. Beta-blockers for chest pain associated with recent cocaine use. Arch Intern Med. 2010;170:874-879.

12. Gupta AK, Greller HA, Hoffman RS. Beta-blockers and cocaine: still a bad idea. Arch Intern Med. 2010;170:1859-1860; author reply 60.

13. Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a ‘coma cocktail’. JAMA. 1995;274:562-569.

14. Hack JB, Hoffman RS. Thiamine before glucose to prevent Wernicke encephalopathy: examining the conventional wis-dom. JAMA. 1998;279:583-584.

15. Koguchi K, Nakatsuji Y, Abe K, et al. Wernicke’s encephalopathy after glucose infusion. Neurology. 2004;62:512.

16. Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med. 1983;12:438-445.

17. Robertson TM, Hendey GW, Stroh G, et al. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009;13:512-515.

18. Mycyk MB, Szyszko AL, Aks SE. Nebulized naloxone gently and effectively reverses methadone intoxication. J Emerg Med. 2003;24:185-187.

19. Schwartz JA, Koenigsberg MD. Naloxone-induced pulmonary edema. Ann Emerg Med. 1987;16:1294-1296.

20. Longmire AW, Seger DL. Topics in clinical pharmacology: fluma-zenil, a benzodiazepine antagonist. Am J Med Sci. 1993;306:49-52.

21. Mordel A, Winkler E, Almog S, et al. Seizures after flumazenil administration in a case of combined benzodiazepine and tricy-clic antidepressant overdose. Crit Care Med. 1992;20:1733-1734.

22. Derlet RW, Albertson TE. Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications. Ann Emerg Med. 1994;23:494-498.

23. Weinbroum A, Rudick V, Sorkine P, et al. Use of flumazenil in the treatment of drug overdose: a double-blind and open clini-cal study in 110 patients. Crit Care Med. 1996;24:199-206.

24. Barnett R, Grace M, Boothe P, et al. Flumazenil in drug over-dose: randomized, placebo-controlled study to assess cost effec-tiveness. Crit Care Med. 1999;27:78-81.

25. Hadad E, Weinbroum AA, Ben-Abraham R. Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med. 2003;10:149-154.

26. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syn-drome. Am J Psychiatry. 2007;164:870-876.

27. Wright N. An assessment of the unreliability of the history given by self-poisoned patients. Clin Toxicol. 1980;16:381-384.

28. Meehan TJ, Bryant SM, Aks SE. Drugs of abuse: the highs and lows of altered mental states in the emergency department. Emerg Med Clin North Am. 2010;28:663-682.

29. Erickson TB, Thompson TM, Lu JJ. The approach to the patient with an unknown overdose. Emerg Med Clin North Am. 2007;25:249-281; abstract vii.

Section11-O-Ref.indd 1 12/10/2014 8:08:23 PM

References2

30. Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. Arch Intern Med. 1990;150:311-313.

31. Oh MS, Carroll HJ. The anion gap. N Engl J Med. 1977;297: 814-817.

32. Gabow PA. Disorders associated with an altered anion gap. Kidney Int. 1985;27:472-483.

33. Gabow PA, Clay K, Sullivan JB, et al. Organic acids in ethylene glycol intoxication. Ann Intern Med. 1986;105:16-20.

34. Leatherman JW, Schmitz PG. Fever, hyperdynamic shock, and multiple-system organ failure. A pseudo-sepsis syndrome associated with chronic salicylate intoxication. Chest. 1991;100: 1391-1396.

35. Walker JA, Schwartzbard A, Krauss EA, et al. The missing gap. A pitfall in the diagnosis of alcohol intoxication by osmometry. Arch Intern Med. 1986;146:1843-1844.

36. Sweeney TE, Beuchat CA. Limitations of methods of osmom-etry: measuring the osmolality of biological fluids. Am J Physiol. 1993;264:R469-R480.

37. Glasser L, Sternglanz PD, Combie J, et al. Serum osmolality and its applicability to drug overdose. Am J Clin Pathol. 1973;60: 695-699.

38. Glaser DS. Utility of the serum osmol gap in the diagnosis of methanol or ethylene glycol ingestion. Ann Emerg Med. 1996;27:343-346.

39. Trummel J, Ford M, Austin P. Ingestion of an unknown alcohol. Ann Emerg Med. 1996;27:368-374.

40. Hoffman RS, Smilkstein MJ, Howland MA, et al. Osmol gaps revisited: normal values and limitations. J Toxicol Clin Toxicol. 1993;31:81-93.

41. Mycyk MB, Aks SE. A visual schematic for clarifying the tem-poral relationship between the anion and osmol gaps in toxic alcohol poisoning. Am J Emerg Med. 2003;21:333-335.

42. Ammar KA, Heckerling PS. Ethylene glycol poisoning with a normal anion gap caused by concurrent ethanol ingestion: importance of the osmolal gap. Am J Kidney Dis. 1996;27: 130-133.

43. Schelling JR, Howard RL, Winter SD, et al. Increased osmolal gap in alcoholic ketoacidosis and lactic acidosis. Ann Intern Med. 1990;113:580-582.

44. Sklar AH, Linas SL. The osmolal gap in renal failure. Ann Intern Med. 1983;98:481-482.

45. Tillman DJ, Ruggles DL, Leikin JB. Radiopacity study of extended-release formulations using digitalized radiography. Am J Emerg Med. 1994;12:310-314.

46. Brett AS. Implications of discordance between clinical impres-sion and toxicology analysis in drug overdose. Arch Intern Med. 1988;148:437-441.

47. Kellermann AL, Fihn SD, LoGerfo JP, et al. Impact of drug screening in suspected overdose. Ann Emerg Med. 1987;16: 1206-1216.

48. Gibb K. Serum alcohol levels, toxicology screens, and use of the breath alcohol analyzer. Ann Emerg Med. 1986;15:349-353.

49. Mahoney JD, Gross PL, Stern TA, et al. Quantitative serum toxic screening in the management of suspected drug overdose. Am J Emerg Med. 1990;8:16-22.

50. Wigder HN, Erickson T, Morse T, et al. Emergency depart-ment poison advice telephone calls. Ann Emerg Med. 1995;25: 349-352.

51. Position paper: Ipecac syrup. J Toxicol Clin Toxicol. 2004;42: 133-143.

52. Manoguerra AS, Cobaugh DJ. Guideline on the use of ipecac syrup in the out-of-hospital management of ingested poisons. Clin Toxicol (Phila). 2005;43:1-10.

53. Vale JA, Kulig K. Position paper: gastric lavage. J Toxicol Clin Toxicol. 2004;42:933-943.

54. Rudolph JP. Automated gastric lavage and a comparison of 0.9% normal saline solution and tap water irrigant. Ann Emerg Med. 1985;14:1156-1159.

55. Olson KR. Activated charcoal for acute poisoning: one toxicolo-gist’s journey. J Med Toxicol. 2010;6:190-198.

56. Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose acti-vated charcoal in acute self-poisoning: a randomised controlled trial. Lancet. 2008;371:579-587.

57. Underhill TJ, Greene MK, Dove AF. A comparison of the effi-cacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Arch Emerg Med. 1990;7:148-154.

58. Spiller HA, Sawyer TS. Impact of activated charcoal after acute acetaminophen overdoses treated with N-acetylcysteine. J Emerg Med. 2007;33:141-144.

59. Jurgens G, Hoegberg LC, Graudal NA. The effect of activated charcoal on drug exposure in healthy volunteers: a meta- analysis. Clin Pharmacol Ther. 2009;85:501-505.

60. Chyka PA, Seger D, Krenzelok EP, et al. Position paper: single-dose activated charcoal. Clin Toxicol (Phila). 2005;43:61-87.

61. Greene S, Harris C, Singer J. Gastrointestinal decontamination of the poisoned patient. Pediatr Emerg Care. 2008;24:176-186; quiz 187-189.

62. Givens T, Holloway M, Wason S. Pulmonary aspiration of activated charcoal: a complication of its misuse in overdose management. Pediatr Emerg Care. 1992;8:137-140.

63. Elliott CG, Colby TV, Kelly TM, et al. Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal. Chest. 1989;96:672-674.

64. Harris CR, Filandrinos D. Accidental administration of acti-vated charcoal into the lung: aspiration by proxy. Ann Emerg Med. 1993;22:1470-1473.

65. Menzies DG, Busuttil A, Prescott LF. Fatal pulmonary aspira-tion of oral activated charcoal. BMJ. 1988;297:459-460.

66. Bradberry SM, Vale JA. Multiple-dose activated charcoal: a review of relevant clinical studies. J Toxicol Clin Toxicol. 1995;33:407-416.

67. Mokhlesi B, Leiken JB, Murray P, et al. Adult toxicology in critical care: part I: general approach to the intoxicated patient. Chest. 2003;123:577-592.

68. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poi-soning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1999;37:731-751.

69. Ilkhanipour K, Yealy DM, Krenzelok EP. The comparative effi-cacy of various multiple-dose activated charcoal regimens. Am J Emerg Med. 1992;10:298-300.

70. Keller RE, Schwab RA, Krenzelok EP. Contribution of sorbitol combined with activated charcoal in prevention of salicylate absorption. Ann Emerg Med. 1990;19:654-656.

Section11-O-Ref.indd 2 12/10/2014 8:08:24 PM

References 3

71. McNamara RM, Aaron CK, Gemborys M, et al. Sorbitol catharsis does not enhance efficacy of charcoal in a simulated acetaminophen overdose. Ann Emerg Med. 1988;17:243-246.

72. Barceloux D, McGuigan M, Hartigan-Go K. Position statement: cathartics. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997;35:743-752.

73. Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;42:843-854.

74. Goldfrank LR, Flomenbaum N. Goldfrank’s Toxicologic Emergencies. 8th ed. New York: McGraw-Hill, Medical Pub Division; 2006.

75. Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42:1-26.

76. Ismail N, Becker BN. Common poisoning and drug overdose. In: Jacobson HR, Striker JE, Klahr S, eds. The Principles and Practice of Nephrology. 2nd ed. St Louis, MO: Mosby; 1995:726.

77. Winchester JF: Active methods for detoxification. In: Haddad LM, Winchester JF, eds. Clinical Management of Poisoning and Drug Overdose. 2nd ed. Philadelphia, PA: Saunders; 1990:174.

78. Garella S. Extracorporeal techniques in the treatment of exog-enous intoxications. Kidney Int. 1988;33:735-754.

79. Pond SM. Diuresis, dialysis, and hemoperfusion: indications and benefits. Emerg Med Clin North Am. 1984;2:29-45.

80. Pond SM. Extracorporeal techniques in the treatment of poisoned patients. Med J Aust. 1991;154:617-622.

81. Winchester JF. Use of dialysis and hemoperfusion in treatment of poisoning. In: Daugirdas JT, Ing TS, eds. Handbook of Dialysis. 2nd ed. Boston, MA: Little, Brown; 1994:569.

82. Gwilt PR, Perrier D. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clin Pharmacol Ther. 1978;24:154-161.

83. Blye E, Lorch J, Cortell S. Extracorporeal therapy in the treatment of intoxication. Am J Kidney Dis. 1984;3:321-338.

84. Tilstone WJ, Winchester JF, Reavey PC. The use of pharmaco-kinetic principles in determining the effectiveness of removal of toxins from blood. Clin Pharmacokinet. 1979;4:23-37.

85. Alexander DP, Gambertoglio JG: Drug overdose and pharma-cologic considerations in dialysis. In: Cogan MG, Garovoy MR, eds. Introduction to Dialysis. New York: Churchill Livingston; 1985:261.

86. Aronoff GR, Brier ME. Prescribing drugs for dialysis patients. In: Henrich WL, ed. Principles and Practice of Dialysis. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:147.

87. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis. 1992;20:354-360.

88. Touchette MA, Patel RV, Anandan JV, et al. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis. 1995;26:469-474.

89. Winchester JF, Kriger FL. Hemoperfusion. In: Jacobson HR, Striker JE, Klahr S, eds. The Principles and Practice of Nephrology. 2nd ed. St Louis, MO: Mosby; 1995:721.

90. Golper TA, Wedel SK, Kaplan AA, et al. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs. 1985;8:307-312.

91. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic

and therapeutic considerations. Clin Pharmacokinet. 1993; 24:362-379.

92. Golper TA. Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol. 1991;93:110-116.

93. Bellomo R, Kearly Y, Parkin G, et al. Treatment of life- threatening lithium toxicity with continuous arterio-venous hemodiafiltration. Crit Care Med. 1991;19:836-837.

94. Leblanc M, Raymond M, Bonnardeaux A, et al. Lithium poisoning treated by high-performance continuous arterio-venous and venovenous hemodiafiltration. Am J Kidney Dis. 1996;27:365-372.

95. Collee GG, Hanson GC. The management of acute poisoning. Br J Anaesth. 1993;70:562-573.

96. Brett AS, Rothschild N, Gray R, et al. Predicting the clinical course in intentional drug overdose. Implications for use of the intensive care unit. Arch Intern Med. 1987;147:133-137.

97. Kulling P, Persson H. Role of the intensive care unit in the man-agement of the poisoned patient. Med Toxicol. 1986;1:375-386.

98. Manini AF, Hoffman RS. On the Use of Glasgow Coma Scale as a Predictor of ICU Admission in Deliberate Drug Poisoning. Basic Clin Pharmacol Toxicol. 2013; doi: 10.1111/bcpt.12187 (Epub ahead of print).

99. Callaham M. Admission criteria for tricyclic antidepressant ingestion. West J Med. 1982;137:425-429.

100. Linden CH, Rumack BH. Acetaminophen overdose. Emerg Med Clin North Am. 1984;2:103-119.

101. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40:3-20.

102. Rumack BH, Matthew H. Acetaminophen poisoning and toxic-ity. Pediatrics. 1975;55:871-876.

103. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994;272: 1845-1850.

104. Bond GR, Hite LK. Population-based incidence and outcome of acetaminophen poisoning by type of ingestion. Acad Emerg Med. 1999;6:1115-1120.

105. Buckley NA, Whyte IM, O'Connell DL, et al. Activated char-coal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol. 1999;37:753-757.

106. Holubek WJ, Hoffman RS, Goldfarb DS, et al. Use of hemo-dialysis and hemoperfusion in poisoned patients. Kidney Int. 2008;74:1327-1334.

107. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007;11:525-548, vi.

108. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319:1557-1562.

109. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetyl-cysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991;303:1026-1029.

110. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late adminis-tration of acetylcysteine. Lancet. 1990;335:1572-1573.

111. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulmi-nant hepatic failure. N Engl J Med. 1991;324:1852-1857.

Section11-O-Ref.indd 3 12/10/2014 8:08:24 PM

References4

112. Klein-Schwartz W, Doyon S. Intravenous acetylcysteine for the treatment of acetaminophen overdose. Expert Opin Pharmacother. 2011;12:119-130.

113. Woo OF, Mueller PD, Olson KR, et al. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med. 2000;35:363-368.

114. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2:1097-1100.

115. Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med. 1991;20:1058-1063.

116. Martello JL, Pummer TL, Krenzelok EP. Cost minimization analysis comparing enteral N-acetylcysteine to intravenous ace-tylcysteine in the management of acute acetaminophen toxicity. Clin Toxicol (Phila). 2010;48:79-83.

117. Mutimer DJ, Ayres RC, Neuberger JM, et al. Serious paracetamol poisoning and the results of liver transplantation. Gut. 1994;35:809-814.

118. O’Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.

119. Mitchell I, Bihari D, Chang R, et al. Earlier identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med. 1998;26:279-284.

120. Jacobsen D, McMartin KE. Antidotes for methanol and ethylene glycol poisoning. J Toxicol Clin Toxicol. 1997;35:127-143.

121. Gabow PA. Ethylene glycol intoxication. Am J Kidney Dis. 1988;11:277-279.

122. Krenzelok EP, Leikin JB. Approach to the poisoned patient. Dis Mon. 1996;42:509-607.

123. Curtin L, Kraner J, Wine H, et al. Complete recovery after massive ethylene glycol ingestion. Arch Intern Med. 1992;152: 1311-1313.

124. Palmer BF, Eigenbrodt EH, Henrich WL. Cranial nerve deficit: a clue to the diagnosis of ethylene glycol poisoning. Am J Med. 1989;87:91-92.

125. Mallya KB, Mendis T, Guberman A. Bilateral facial paralysis following ethylene glycol ingestion. Can J Neurol Sci. 1986;13: 340-341.

126. Kruse JA. Methanol poisoning. Intensive Care Med. 1992;18: 391-397.

127. Hantson P, Mahieu P. Pancreatic injury following acute metha-nol poisoning. J Toxicol Clin Toxicol. 2000;38:297-303.

128. Brent J. Current management of ethylene glycol poisoning. Drugs. 2001;61:979-988.

129. Megarbane B, Borron SW, Baud FJ. Current recommendations for treatment of severe toxic alcohol poisonings. Intensive Care Med. 2005;31:189-195.

130. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treat-ment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med. 1999;340:832-838.

131. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treat-ment of methanol poisoning. N Engl J Med. 2001;344:424-429.

132. Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40:415-446.

133. Barceloux DG, Krenzelok EP, Olson K, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol. 1999;37:537-560.

134. Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med. 2009;360:2216-2223.

135. Buchanan JA, Alhelail M, Cetaruk EW, et al. Massive ethylene glycol ingestion treated with fomepizole alone-a viable thera-peutic option. J Med Toxicol. 2010;6:131-134.

136. McCoy HG, Cipolle RJ, Ehlers SM, et al. Severe methanol poisoning. Application of a pharmacokinetic model for ethanol therapy and hemodialysis. Am J Med. 1979;67:804-807.

137. Peterson CD, Collins AJ, Himes JM, et al. Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med. 1981;304:21-23.

138. Sabeel AI, Kurkus J, Lindholm T. Intensified dialysis treat-ment of ethylene glycol intoxication. Scand J Urol Nephrol. 1995;29:125-129.

139. Schep LJ, Slaughter RJ, Temple WA, et al. Diethylene glycol poisoning. Clin Toxicol (Phila). 2009;47:525-535.

140. Lacouture PG, Wason S, Abrams A, et al. Acute isopropyl alcohol intoxication. Diagnosis and management. Am J Med. 1983;75:680-686.

141. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856Findings). Rockville, MD. 2010.

142. Jones AL, Simpson KJ. Review article: mechanisms and man-agement of hepatotoxicity in ecstasy (MDMA) and amphet-amine intoxications. Aliment Pharmacol Ther. 1999;13:129-133.

143. Watson JD, Ferguson C, Hinds CJ, et al. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia. 1993;48:1057-1060.

144. Denborough MA, Hopkinson KC. Dantrolene and “ecstasy”. Med J Aust. 1997;166:165-166.

145. Grunau BE, Wiens MO, Brubacher JR. Dantrolene in the treat-ment of MDMA-related hyperpyrexia: a systematic review. CJEM. 2010;12:435-442.

146. Sutherland GR, Park J, Proudfoot AT. Ventilation and acid-base changes in deep coma due to barbiturate or tricyclic antidepres-sant poisoning. Clin Toxicol. 1977;11:403-412.

147. Raymond LW. “Barbiturate blisters” in a case of severe hypogly-caemic coma. Lancet. 1972;2:764.

148. Boldy DA, Vale JA, Prescott LF. Treatment of phenobarbitone poisoning with repeated oral administration of activated char-coal. Q J Med. 1986;61:997-1002.

149. Goldberg MJ, Berlinger WG. Treatment of phenobarbital over-dose with activated charcoal. JAMA. 1982;247:2400-2401.

150. Berg MJ, Berlinger WG, Goldberg MJ, et al. Acceleration of the body clearance of phenobarbital by oral activated charcoal. N Engl J Med. 1982;307:642-644.

151. Mohammed Ebid AH, Abdel-Rahman HM. Pharmacokinetics of phenobarbital during certain enhanced elimination modali-ties to evaluate their clinical efficacy in management of drug overdose. Ther Drug Monit. 2001;23:209-216.

152. Costello JB, Poklis A. Treatment of massive phenobarbital over-dose with dopamine diuresis. Arch Intern Med. 1981;141:938-940.

Section11-O-Ref.indd 4 12/10/2014 8:08:24 PM

References 5

153. Jacobsen D, Wiik-Larsen E, Dahl T, et al. Pharmacokinetic evaluation of haemoperfusion in phenobarbital poisoning. Eur J Clin Pharmacol. 1984;26:109-112.

154. Palmer BF. Effectiveness of hemodialysis in the extracor-poreal therapy of phenobarbital overdose. Am J Kidney Dis. 2000;36:640-643.

155. Nasky KM, Cowan GL, Knittel DR. False-positive urine screen-ing for benzodiazepines: an association with sertraline? A two-year retrospective chart analysis. Psychiatry (Edgmont). 2009;6:36-39.

156. Vincent EC, Zebelman A, Goodwin C, et al. Clinical inquiries. What common substances can cause false positives on urine screens for drugs of abuse? J Fam Pract 2006;55:893-894, 7.

157. Melanson SE, Baskin L, Magnani B, et al. Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. Arch Pathol Lab Med. 2010;134:735-739.

158. Bouget J, Breurec JY, Baert A, et al. Value of charcoal by oral route in patients admitted to emergency department for vol-untary absorption of benzodiazepines. J Toxicol Clin Exp. 1989;9:287-289.

159. Gross JB, Blouin RT, Zandsberg S, et al. Effect of flumazenil on ventilatory drive during sedation with midazolam and alfent-anil. Anesthesiology. 1996;85:713-720.

160. Shalansky SJ, Naumann TL, Englander FA. Effect of flumaze-nil on benzodiazepine-induced respiratory depression. Clin Pharm. 1993;12:483-487.

161. Ngo AS, Anthony CR, Samuel M, et al. Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department? Resuscitation. 2007;74:27-37.

162. Treatment of benzodiazepine overdose with flumazenil. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group. Clin Ther. 1992;14:978-995.

163. Spivey WH, Roberts JR, Derlet RW. A clinical trial of escalating doses of flumazenil for reversal of suspected benzodiazepine overdose in the emergency department. Ann Emerg Med. 1993;22:1813-1821.

164. Weinbroum A, Halpern P, Geller E. The use of flumazenil in the management of acute drug poisoning—a review. Intensive Care Med. 1991;17(suppl 1):S32-S38.

165. Hoffman EJ, Warren EW. Flumazenil: a benzodiazepine antago-nist. Clin Pharm. 1993;12:641-656; quiz 699-701.

166. Agmo A, Galvan A, Heredia A, et al. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology (Berl). 1995;120:186-194.

167. Forster A, Morel D, Bachmann M, et al. Respiratory depressant effects of different doses of midazolam and lack of reversal with naloxone—a double-blind randomized study. Anesth Analg. 1983;62:920-924.

168. Love JN, Litovitz TL, Howell JM, et al. Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. J Toxicol Clin Toxicol. 1997;35:353-359.

169. Love JN. Beta-blocker toxicity: a clinical diagnosis. Am J Emerg Med. 1994;12:356-357.

170. Love JN, Howell JM, Litovitz TL, et al. Acute beta blocker over-dose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000;38:275-281.

171. Love JN. Beta blocker toxicity after overdose: when do symp-toms develop in adults? J Emerg Med. 1994;12:799-802.

172. Reith DM, Dawson AH, Epid D, et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996;34:273-278.

173. Pertoldi F, D’Orlando L, Mercante WP. Electromechanical dis-sociation 48 hours after atenolol overdose: usefulness of calcium chloride. Ann Emerg Med. 1998;31:777-781.

174. Love JN, Hanfling D, Howell JM. Hemodynamic effects of cal-cium chloride in a canine model of acute propranolol intoxica-tion. Ann Emerg Med. 1996;28:1-6.

175. Lipski JI, Kaminsky D, Donoso E, et al. Electrophysiological effects of glucagon on the normal canine heart. Am J Physiol. 1972;222:1107-1112.

176. Love JN, Sachdeva DK, Bessman ES, et al. A potential role for glucagon in the treatment of drug-induced symptomatic brady-cardia. Chest. 1998;114:323-326.

177. Kerns W, 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25:309-331; abstract viii.

178. Kerns W, 2nd, Schroeder D, Williams C, et al. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med. 1997;29:748-757.

179. Sirianni AJ, Osterhoudt KC, Calello DP, et al. Use of lipid emul-sion in the resuscitation of a patient with prolonged cardiovas-cular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med. 2008;51:412-415, 5 e1.

180. Finn SD, Uncles DR, Willers J, et al. Early treatment of a que-tiapine and sertraline overdose with Intralipid. Anaesthesia. 2009;64:191-194.

181. Cave G, Harvey M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med. 2009;16:815-824.

182. Dean P, Ruddy JP, Marshall S. Intravenous lipid emulsion in propanolol overdose. Anaesthesia. 2010;65:1148-1150.

183. Association of Anaesthetists of Great Britain and Ireland. Management of severe local anaesthetic toxicity. http://www.aagbi.org/publications/guidelines/docs/la_toxicity_2010.pdf. Accessed Jan 5, 2011.

184. Kerns W 2nd, Kline J, Ford MD. Beta-blocker and calcium chan-nel blocker toxicity. Emerg Med Clin North Am. 1994;12:365-390.

185. Buckley N, Dawson AH, Howarth D, et al. Slow-release vera-pamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Aust. 1993;158:202-204.

186. Cumpston KL, Aks SE, Sigg T, et al. Whole bowel irrigation and the hemodynamically unstable calcium channel blocker over-dose: primum non nocere. J Emerg Med. 2010;38:171-174.

187. Luscher TF, Noll G, Sturmer T, et al. Calcium gluconate in severe verapamil intoxication. N Engl J Med. 1994;330:718-720.

188. Papadopoulos J, O'Neil MG. Utilization of a glucagon infusion in the management of a massive nifedipine overdose. J Emerg Med. 2000;18:453-455.

189. Wittenberg BA, Wittenberg JB. Effects of carbon monoxide on isolated heart muscle cells. Res Rep Health Eff Inst. 1993:1-12; discussion 3-21.

190. Taitelman U, Schmidt GA: Inhaled toxins. In: Hall JB, Schmidt GA, Wood LD, eds. Principles of Critical Care. New York: McGraw-Hill; 1992:2117.

Section11-O-Ref.indd 5 12/10/2014 8:08:24 PM

References6

191. Dahms TE, Younis LT, Wiens RD, et al. Effects of carbon mon-oxide exposure in patients with documented cardiac arrhyth-mias. J Am Coll Cardiol. 1993;21:442-450.

192. Birky MM, Clarke FB. Inhalation of toxic products from fires. Bull N Y Acad Med. 1981;57:997-1013.

193. Sawa GM, Watson CP, Terbrugge K, et al. Delayed encephalopa-thy following carbon monoxide intoxication. Can J Neurol Sci. 1981;8:77-79.

194. Choi IS. Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol. 1983;40:433-435.

195. Tom T, Abedon S, Clark RI, et al. Neuroimaging characteristics in carbon monoxide toxicity. J Neuroimaging. 1996;6:161-166.

196. Buckley RG, Aks SE, Eshom JL, et al. The pulse oximetry gap in carbon monoxide intoxication. Ann Emerg Med. 1994;24: 252-255.

197. Touger M, Gallagher EJ, Tyrell J. Relationship between venous and arterial carboxyhemoglobin levels in patients with suspected carbon monoxide poisoning. Ann Emerg Med. 1995;25:481-483.

198. Takeuchi A, Vesely A, Rucker J, et al. A simple “new” method to accelerate clearance of carbon monoxide. Am J Respir Crit Care Med. 2000;161:1816-1819.

199. Olson K, Smollin C. Carbon monoxide poisoning (acute). Clin Evid (Online). 2008;2008.

200. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med. 1996;334:1642-1648.

201. Juurlink DN, Buckley NA, Stanbrook MB, et al. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev. 2005:CD002041.

202. Ducasse JL, Celsis P, Marc-Vergnes JP. Non-comatose patients with acute carbon monoxide poisoning: hyperbaric or normo-baric oxygenation? Undersea Hyperb Med. 1995;22:9-15.

203. Annane D, Chadda K, Gajdos P, et al. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med. 2010;37(3): 486-492.

204. Gorman DF, Clayton D, Gilligan JE, et al. A longitudinal study of 100 consecutive admissions for carbon monoxide poison-ing to the Royal Adelaide Hospital. Anaesth Intensive Care. 1992;20:311-316.

205. Cregler LL, Mark H. Medical complications of cocaine abuse. N Engl J Med. 1986;315:1495-1500.

206. Wilson LD, Henning RJ, Suttheimer C, et al. Cocaethylene causes dose-dependent reductions in cardiac function in anes-thetized dogs. J Cardiovasc Pharmacol. 1995;26:965-973.

207. Harris DS, Everhart ET, Mendelson J, et al. The pharmacol-ogy of cocaethylene in humans following cocaine and ethanol administration. Drug Alcohol Depend. 2003;72:169-182.

208. Goldstein RA, DesLauriers C, Burda AM. Cocaine: history, social implications, and toxicity—a review. Dis Mon. 2009;55: 6-38.

209. Reeves RR, McWilliams ME, Fitz-Gerald M. Cocaine-induced ischemic cerebral infarction mistaken for a psychiatric syn-drome. South Med J. 1995;88:352-354.

210. Nolte KB, Brass LM, Fletterick CF. Intracranial hemorrhage associated with cocaine abuse: a prospective autopsy study. Neurology. 1996;46:1291-1296.

211. Daras M, Tuchman AJ, Koppel BS, et al. Neurovascular compli-cations of cocaine. Acta Neurol Scand. 1994;90:124-129.

212. Lalouschek W, Schnider P, Aull S, et al. Cocaine abuse—with special reference to cerebrovascular complications. Wien Klin Wochenschr. 1995;107:516-521.

213. Chang RA, Rossi NF. Intermittent cocaine use associated with recurrent dissection of the thoracic and abdominal aorta. Chest. 1995;108:1758-1762.

214. Willens HJ, Chakko SC, Kessler KM. Cardiovascular manifesta-tions of cocaine abuse. A case of recurrent dilated cardiomyopa-thy. Chest. 1994;106:594-600.

215. Bosch X, Loma-Osorio P, Guasch E, et al. Prevalence, clinical characteristics and risk of myocardial infarction in patients with cocaine-related chest pain. Rev Esp Cardiol. 2010;63:1028-1034.

216. Fraker TD Jr, Temesy-Armos PN, Brewster PS, et al. Interaction of propranolol, verapamil, and nifedipine on the myocar-dial depressant effect of cocaine. J Cardiovasc Pharmacol. 1995;25:579-586.

217. Chakko S, Myerburg RJ. Cardiac complications of cocaine abuse. Clin Cardiol. 1995;18:67-72.

218. Hollander JE, Hoffman RS, Gennis P, et al. Prospective mul-ticenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Acad Emerg Med. 1994;1:330-339.

219. Mohamad T, Niraj A, Farah J, et al. Spectrum of electrocardio-graphic and angiographic coronary artery disease findings in patients with cocaine-associated myocardial infarction. Coron Artery Dis. 2009;20:332-336.

220. Trabulsy ME. Cocaine washed out syndrome in a patient with acute myocardial infarction. Am J Emerg Med. 1995;13:538-539.

221. Hollander JE, Hoffman RS, Gennis P, et al. Cocaine-associated chest pain: one-year follow-up. Acad Emerg Med. 1995;2: 179-184.

222. Fortney JC, Tripathi SP, Walton MA, et al. Patterns of substance abuse treatment seeking following cocaine-related emergency department visits. J Behav Health Serv Res. 2010;38(2):221-233.

223. Averbach M, Casey KK, Frank E. Near-fatal status asth-maticus induced by nasal insufflation of cocaine. South Med J. 1996;89:340-341.

224. Silverman RS, Lee-Chiong TL Jr, Sherter CB. Stridor from edema of the arytenoids, epiglottis, and vocal cords after use of free-base cocaine. Chest. 1995;108:1477-1478.

225. Yakel DL Jr, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J. 1995;130: 398-399.

226. Albertson TE, Walby WF, Derlet RW. Stimulant-induced pul-monary toxicity. Chest. 1995;108:1140-1149.

227. Forrester JM, Steele AW, Waldron JA, et al. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histo-pathologic findings. Am Rev Respir Dis. 1990;142:462-467.

228. Daras M, Kakkouras L, Tuchman AJ, et al. Rhabdomyolysis and hyperthermia after cocaine abuse: a variant of the neuroleptic malignant syndrome? Acta Neurol Scand. 1995;92:161-165.

229. Roth D, Alarcon FJ, Fernandez JA, et al. Acute rhabdomy-olysis associated with cocaine intoxication. N Engl J Med. 1988;319:673-677.

230. Sanjuanbenito Dehesa A, Fernandez Cebrian JM. Ischaemic colitis induced by cocaine abuse. Br J Surg. 1995;82:138.

231. Goodman PE, Rennie WP. Renal infarction secondary to nasal insufflation of cocaine. Am J Emerg Med. 1995;13:421-423.

Section11-O-Ref.indd 6 12/10/2014 8:08:25 PM

References 7

232. Kudrow DB, Henry DA, Haake DA, et al. Botulism associated with Clostridium botulinum sinusitis after intranasal cocaine abuse. Ann Intern Med. 1988;109:984-985.

233. MacDonald KL, Rutherford GW, Friedman SM, et al. Botulism and botulism-like illness in chronic drug abusers. Ann Intern Med. 1985;102:616-618.

234. Marzuk PM, Tardiff K, Leon AC, et al. Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med. 1995;332:1753-1757.

235. Booker RJ, Smith JE, Rodger MP. Packers, pushers and stuffers—managing patients with concealed drugs in UK emergency departments: a clinical and medicolegal review. Emerg Med J. 2009;26:316-320.

236. Hoffman RS, Smilkstein MJ, Goldfrank LR. Whole bowel irriga-tion and the cocaine body-packer: a new approach to a common problem. Am J Emerg Med. 1990;8:523-527.

237. Brown JA, Phang PT, Enns R, et al. Computed tomography to detect body packing: an unusual cause of small bowel obstruc-tion. Can Assoc Radiol J. 2002;53:84-86.

238. Makosiej FJ, Hoffman RS, Howland MA, et al. An in vitro evalu-ation of cocaine hydrochloride adsorption by activated charcoal and desorption upon addition of polyethylene glycol electrolyte lavage solution. J Toxicol Clin Toxicol. 1993;31:381-395.

239. Glass JM, Scott HJ. ‘Surgical mules’: the smuggling of drugs in the gastrointestinal tract. J R Soc Med. 1995;88:450-453.

240. Catravas JD, Waters IW. Acute cocaine intoxication in the con-scious dog: studies on the mechanism of lethality. J Pharmacol Exp Ther. 1981;217:350-356.

241. Brogan WC 3rd, Lange RA, Kim AS, et al. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. J Am Coll Cardiol. 1991;18:581-586.

242. Hollander JE. The management of cocaine-associated myocar-dial ischemia. N Engl J Med. 1995;333:1267-1272.

243. Hollander JE, Carter WA, Hoffman RS. Use of phentolamine for cocaine-induced myocardial ischemia. N Engl J Med. 1992;327:361.

244. Dattilo PB, Hailpern SM, Fearon K, et al. Beta-blockers are asso-ciated with reduced risk of myocardial infarction after cocaine use. Ann Emerg Med. 2008;51:117-125.

245. Shih RD, Hollander JE, Burstein JL, et al. Clinical safety of lido-caine in patients with cocaine-associated myocardial infarction. Ann Emerg Med. 1995;26:702-706.

246. Hollander JE, Burstein JL, Hoffman RS, et al. Cocaine-associated myocardial infarction. Clinical safety of thrombolytic ther-apy. Cocaine Associated Myocardial Infarction (CAMI) Study Group. Chest. 1995;107:1237-1241.

247. Akintonwa A, Tunwashe OL. Fatal cyanide poisoning from cassava-based meal. Hum Exp Toxicol. 1992;11:47-49.

248. Logan B, Howard J, Kiesel EL. Poisonings associated with cya-nide in over the counter cold medication in Washington State, 1991. J Forensic Sci. 1993;38:472-476.

249. Saeui C, Charlton N, Brady WJ. Biochemical issues in emergency medicine: diagnostic and therapeutic considerations of selected toxic presentations. Am J Emerg Med. 2012;30(1):231-235.

250. Yen D, Tsai J, Wang LM, et al. The clinical experience of acute cyanide poisoning. Am J Emerg Med. 1995;13:524-528.

251. Salkowski AA, Penney DG. Cyanide poisoning in animals and humans: a review. Vet Hum Toxicol. 1994;36:455-466.

252. Yeh MM, Becker CE, Arieff AI. Is measurement of venous oxy-gen saturation useful in the diagnosis of cyanide poisoning? Am J Med. 1992;93:582-583.

253. Benowitz NL. Nitroprusside. In: Olson KR, ed. Poisoning and Drug Overdose. 2nd ed. Norwalk, CT: Appleton & Lange; 1994:231.

254. Blanc PD. Cyanide. In: Olson KR, ed. Poisoning and Drug Overdose. 2nd ed. Norwalk, CT: Appleton & Lange; 1994:145.

255. Cope C. The importance of oxygen in the treatment of cyanide poisoning. JAMA. 1961;175:1061-1064.

256. Isom GE, Way JL. Effect of oxygen on cyanide intoxication. VI. Reactivation of cyanide-inhibited glucose metabolism. J Pharmacol Exp Ther. 1974;189:235-243.

257. Litovitz TL, Larkin RF, Myers RA. Cyanide poisoning treated with hyperbaric oxygen. Am J Emerg Med. 1983;1:94-101.

258. Lawson-Smith P, Jansen EC, Hilsted L, et al. Effect of hyperbaric oxygen therapy on whole blood cyanide concentrations in car-bon monoxide intoxicated patients from fire accidents. Scand J Trauma Resusc Emerg Med. 2010;18:32.

259. Way JL, End E, Sheehy MH, et al. Effect of oxygen on cyanide intoxication. IV. Hyperbaric oxygen. Toxicol Appl Pharmacol. 1972;22:415-421.

260. Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med. 1993;22:1413-1418.

261. Hoffman RS, Sauter D. Methemoglobinemia resulting from smoke inhalation. Vet Hum Toxicol. 1989;31:168-170.

262. Westley J, Adler H, Westley L, et al. The sulfurtransferases. Fundam Appl Toxicol. 1983;3:377-382.

263. Robin ED, McCauley R. Nitroprusside-related cyanide poison-ing. Time (long past due) for urgent, effective interventions. Chest. 1992;102:1842-1845.

264. Hall VA, Guest JM. Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate prophy-laxis. Am J Crit Care. 1992;1:19-25; quiz 6-7.

265. Borron SW, Baud FJ, Megarbane B, et al. Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med. 2007;25:551-558.

266. Bebarta VS, Tanen DA, Lairet J, et al. Hydroxocobalamin and sodium thiosulfate versus sodium nitrite and sodium thiosul-fate in the treatment of acute cyanide toxicity in a swine (Sus scrofa) model. Ann Emerg Med. 2010;55:345-351.

267. Beckerman N, Leikin SM, Aitchinson R, et al. Laboratory inter-ferences with the newer cyanide antidote: hydroxocobalamin. Semin Diagn Pathol. 2009;26:49-52.

268. Zerbe NF, Wagner BK. Use of vitamin B12 in the treatment and prevention of nitroprusside-induced cyanide toxicity. Crit Care Med. 1993;21:465-467.

269. Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. 1985;313:474-479.

270. Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. 1995;26:195-201.

271. Stern TA, O'Gara PT, Mulley AG, et al. Complications after overdose with tricyclic antidepressants. Crit Care Med. 1985;13: 672-674.

Section11-O-Ref.indd 7 12/10/2014 8:08:25 PM

References8

272. Callaham M, Kassel D. Epidemiology of fatal tricyclic antide-pressant ingestion: implications for management. Ann Emerg Med. 1985;14:1-9.

273. Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9:588-590.

274. Woolf AD, Erdman AR, Nelson LS, et al. Tricyclic antidepres-sant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45:203-233.

275. McDuffee AT, Tobias JD. Seizure after flumazenil administra-tion in a pediatric patient. Pediatr Emerg Care. 1995;11:186-187.

276. Tran TP, Panacek EA, Rhee KJ, et al. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypoten-sion. Acad Emerg Med. 1997;4:864-868.

277. Engels PT, Davidow JS. Intravenous fat emulsion to reverse hae-modynamic instability from intentional amitriptyline overdose. Resuscitation. 2010;81:1037-1039.

278. Lindenbaum J, Rund DG, Butler VP Jr, et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305:789-794.

279. Centers for Disease Control and Prevention. Deaths associated with a purported aphrodisiac—New York City, February 1993-May 1995. JAMA. 1995;274:1828-1829.

280. Lewis RP. Clinical use of serum digoxin concentrations. Am J Cardiol. 1992;69:97G-106G; discussion G-7G.

281. Smith TW. Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. Am J Med. 1975;58:470-476.

282. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical ben-efits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39:946-953.

283. Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81:1744-1752.

284. Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36:3014-3018.

285. Ujhelyi MR, Robert S, Cummings DM, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med. 1993;119:273-277.

286. Rabetoy GM, Price CA, Findlay JW, et al. Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis. Am J Nephrol. 1990;10:518-521.

287. Levine M, Nikkanen H, Pallin DJ. The effects of intrave-nous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40(1):41-46.

288. Hack JB, Woody JH, Lewis DE, et al. The effect of calcium chlo-ride in treating hyperkalemia due to acute digoxin toxicity in a porcine model. J Toxicol Clin Toxicol. 2004;42:337-342.

289. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB)—a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35:581-590.

290. Pardi D, Black J. Gamma-hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs. 2006;20:993-1018.

291. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimula-tion of slow-wave sleep and growth hormone secretion by

gamma-hydroxybutyrate in normal young Men. J Clin Invest. 1997;100:745-753.

292. Lammers GJ, Arends J, Declerck AC, et al. Gammahydroxy-butyrate and narcolepsy: a double-blind placebo-controlled study. Sleep. 1993;16:216-220.

293. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate with-drawal syndrome. Ann Emerg Med. 2001;37:147-153.

294. Davis LG. Fatalities attributed to GHB and related compounds. South Med J. 1999;92:1037.

295. Chin RL, Sporer KA, Cullison B, et al. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med. 1998;31:716-722.

296. Munir VL, Hutton JE, Harney JP, et al. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas. 2008;20:521-530.

297. Yates SW, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc. 2000;75:401-402.

298. Bania TC, Chu J. Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma- hydroxybutyrate intoxication. Acad Emerg Med. 2005;12:185-189.

299. Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review. J Toxicol Clin Toxicol. 2002;40:781-787.

300. Zvosec DL, Smith SW, Litonjua R, et al. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol (Phila). 2007;45:261-265.

301. ElSohly MA, Salamone SJ. Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol. 1999;23:141-146.

302. LeBeau MA, Montgomery MA, Miller ML, et al. Analysis of biofluids for gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) by headspace GC-FID and GC-MS. J Anal Toxicol. 2000;24:421-428.

303. Okusa MD, Crystal LJ. Clinical manifestations and man-agement of acute lithium intoxication. Am J Med. 1994;97: 383-389.

304. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs. 2009;23:397-418.

305. Dawson AH, Whyte IM. Therapeutic drug monitoring in drug overdose. Br J Clin Pharmacol. 2001;52(suppl 1):97S-102S.

306. Favin FD, Klein-Schwartz W, Oderda GM, et al. In vitro study of lithium carbonate adsorption by activated charcoal. J Toxicol Clin Toxicol. 1988;26:443-450.

307. Linakis JG, Lacouture PG, Eisenberg MS, et al. Administration of activated charcoal or sodium polystyrene sulfonate (Kayexalate) as gastric decontamination for lithium intoxication: an animal model. Pharmacol Toxicol. 1989;65:387-389.

308. Watling SM, Gehrke JC, Gehrke CW, et al. In vitro binding of lithium using the cation exchange resin sodium polystyrene sulfonate. Am J Emerg Med. 1995;13:294-296.

309. Ghannoum M, Lavergne V, Yue CS, et al. Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retro-spective cohort study. Clin Toxicol (Phila). 2010;48:34-41.

310. Smith SW, Ling LJ, Halstenson CE. Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med. 1991;20:536-539.

311. Amdisen A. Clinical features and management of lithium poi-soning. Med Toxicol Adverse Drug Exp. 1988;3:18-32.

Section11-O-Ref.indd 8 12/10/2014 8:08:25 PM

References 9

312. Jaeger A, Sauder P, Kopferschmitt J, et al. When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. J Toxicol Clin Toxicol. 1993;31:429-447.

313. Clendeninn NJ, Pond SM, Kaysen G, et al. Potential pitfalls in the evaluation of the usefulness of hemodialysis for the removal of lithium. J Toxicol Clin Toxicol. 1982;19:341-352.

314. Friedberg RC, Spyker DA, Herold DA. Massive overdoses with sustained-release lithium carbonate preparations: phar-macokinetic model based on two case studies. Clin Chem. 1991;37:1205-1209.

315. Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol. 1993;42:7-12.

316. Fairbanks VF. Blue gods, blue oil, and blue people. Mayo Clin Proc. 1994;69:889-892.

317. Watcha MF, Connor MT, Hing AV. Pulse oximetry in methemo-globinemia. Am J Dis Child. 1989;143:845-847.

318. Barker SJ, Tremper KK, Hyatt J. Effects of methemoglobinemia on pulse oximetry and mixed venous oximetry. Anesthesiology. 1989;70:112-117.

319. Donnelly GB, Randlett D. Images in clinical medicine. Methemoglobinemia. N Engl J Med. 2000;343:337.

320. Rehman HU. Methemoglobinemia. West J Med. 2001;175: 193-196.

321. Shah NG, Lathrop SL, Reichard RR, et al. Unintentional drug overdose death trends in New Mexico, USA, 1990-2005: com-binations of heroin, cocaine, prescription opioids and alcohol. Addiction. 2008;103:126-136.

322. Green TC, Grau LE, Carver HW, et al. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997-2007. Drug Alcohol Depend. 2010.

323. Ruttenber AJ, Kalter HD, Santinga P. The role of ethanol abuse in the etiology of heroin-related death. J Forensic Sci. 1990;35:891-900.

324. Sternbach G. William Osler: narcotic-induced pulmonary edema. J Emerg Med. 1983;1:165-167.

325. Cygan J, Trunsky M, Corbridge T. Inhaled heroin-induced sta-tus asthmaticus: five cases and a review of the literature. Chest. 2000;117:272-275.

326. Krantz AJ, Hershow RC, Prachand N, et al. Heroin insufflation as a trigger for patients with life-threatening asthma. Chest. 2003;123:510-517.

327. Hershey LA. Meperidine and central neurotoxicity. Ann Intern Med. 1983;98:548-549.

328. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med. 1991;20:246-252.

329. Mullins M, Froelke BR, Rivera MR. Effect of delayed activated charcoal on acetaminophen concentration after simulated over-dose of oxycodone and acetaminophen. Clin Toxicol (Phila). 2009;47:112-115.

330. Merriman T, Stokes K. Small bowel obstruction secondary to administration of activated charcoal. Aust N Z J Surg. 1995;65:288-289.

331. Tandberg D, Abercrombie D. Treatment of heroin overdose with endotracheal naloxone. Ann Emerg Med. 1982;11:443-445.

332. Schumann H, Erickson T, Thompson TM, et al. Fentanyl epi-demic in Chicago, Illinois and surrounding Cook County. Clin Toxicol (Phila). 2008;46:501-506.

333. Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema: a case series. Chest. 2001;120:1628-1632.

334. Rosman Y, Makarovsky I, Bentur Y, et al. Carbamate poisoning: treatment recommendations in the setting of a mass casualties event. Am J Emerg Med. 2009;27:1117-1124.

335. Namba T, Nolte CT, Jackrel J, et al. Poisoning due to organo-phosphate insecticides. Acute and chronic manifestations. Am J Med. 1971;50:475-492.

336. Sungur M, Guven M. Intensive care management of organophosphate insecticide poisoning. Crit Care. 2001;5: 211-215.

337. Wu ML, Deng JF, Tsai WJ, et al. Food poisoning due to methamidophos-contaminated vegetables. J Toxicol Clin Toxicol. 2001;39:333-336.

338. Geller RJ, Singleton KL, Tarantino ML, et al. Nosocomial poisoning associated with emergency department treatment of organophosphate toxicity—Georgia, 2000. J Toxicol Clin Toxicol. 2001;39:109-111.

339. Hayes MM, van der Westhuizen NG, Gelfand M. Organophosphate poisoning in Rhodesia. A study of the clini-cal features and management of 105 patients. S Afr Med J. 1978;54:230-234.

340. Roberts DM, Aaron CK. Management of acute organophospho-rus pesticide poisoning. BMJ. 2007;334:629-634.

341. Nouira S, Abroug F, Elatrous S, et al. Prognostic value of serum cholinesterase in organophosphate poisoning. Chest. 1994;106:1811-1814.

342. Coye MJ, Barnett PG, Midtling JE, et al. Clinical confirmation of organophosphate poisoning by serial cholinesterase analyses. Arch Intern Med. 1987;147:438-442.

343. Bardin PG, Van Eeden SF. Organophosphate poisoning: grad-ing the severity and comparing treatment between atropine and glycopyrrolate. Crit Care Med. 1990;18:956-960.

344. Arendse R, Irusen E. An atropine and glycopyrrolate combina-tion reduces mortality in organophosphate poisoning. Hum Exp Toxicol. 2009;28:715-720.

345. Farago A. Fatal suicidal case of Sevin (1-naphthyl-N-methyl-carbamate) poisoning. Arch Toxikol. 1969;24:309-315.

346. Done AK. Salicylate intoxication. Significance of measurements of salicylate in blood in cases of acute ingestion. Pediatrics. 1960;26:800-807.

347. Chan TY. Improvements in the packaging of drugs and chemi-cals may reduce the likelihood of severe intentional poisonings in adults. Hum Exp Toxicol. 2000;19:387-391.

348. Hawton K, Townsend E, Deeks J, et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ. 2001;322:1203-1207.

349. Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med. 1981;141:364-369.

350. Gabow PA, Anderson RJ, Potts DE, et al. Acid-base distur-bances in the salicylate-intoxicated adult. Arch Intern Med. 1978;138:1481-1484.

351. Hill JB. Salicylate intoxication. N Engl J Med. 1973;288: 1110-1113.

352. Chyka PA, Erdman AR, Christianson G, et al. Salicylate poison-ing: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45:95-131.

Section11-O-Ref.indd 9 12/10/2014 8:08:25 PM

References10

353. Thisted B, Krantz T, Stroom J, et al. Acute salicylate self- poisoning in 177 consecutive patients treated in ICU. Acta Anaesthesiol Scand. 1987;31:312-316.

354. McGuigan MA. A two-year review of salicylate deaths in Ontario. Arch Intern Med. 1987;147:510-512.

355. Dargan PI, Wallace CI, Jones AL. An evidence-based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J. 2002;19:206-209.

356. Anderson RJ, Potts DE, Gabow PA, et al. Unrecognized adult salicylate intoxication. Ann Intern Med. 1976;85:745-748.

357. Greer HD, 3rd, Ward HP, Corbin KB. Chronic salicylate intoxication in adults. JAMA. 1965;193:555-558.

358. Heffner JE, Sahn SA. Salicylate-induced pulmonary edema. Clinical features and prognosis. Ann Intern Med. 1981;95: 405-409.

359. Hoffman RJ, Nelson LS, Hoffman RS. Use of ferric chloride to identify salicylate-containing poisons. J Toxicol Clin Toxicol. 2002;40:547-549.

360. Prescott LF, Balali-Mood M, Critchley JA, et al. Diuresis or uri-nary alkalinisation for salicylate poisoning? Br Med J (Clin Res Ed). 1982;285:1383-1386.

361. O’Malley GF. Emergency department management of the salicylate-poisoned patient. Emerg Med Clin North Am. 2007;25:333-346; abstract viii.

362. Kuzak N, Brubacher JR, Kennedy JR. Reversal of salicylate-induced euglycemic delirium with dextrose. Clin Toxicol (Phila). 2007;45:526-529.

363. Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med. 2008;15:866-869.

364. Corkeron MA. Serotonin syndrome—a potentially fatal compli-cation of antidepressant therapy. Med J Aust. 1995;163:481-482.

365. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.

366. Yilmaz Z, Ceschi A, Rauber-Luthy C, et al. Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol (Phila). 2010;48:207-212.

367. van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009;54:404-408.

368. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635-642.

369. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.

370. Ables AZ, Nagubilli R. Prevention, recognition, and manage-ment of serotonin syndrome. Am Fam Physician. 2010;81: 1139-1142.

371. Taylor IC, McConnell JG. Severe hyponatraemia associated with selective serotonin reuptake inhibitors. Scott Med J. 1995;40:147-148.

372. Goldstein L, Barker M, Segall F, et al. Seizure and transient SIADH associated with sertraline. Am J Psychiatry. 1996;153:732.

373. Lappin RI, Auchincloss EL. Treatment of the serotonin syn-drome with cyproheptadine. N Engl J Med. 1994;331:1021-1022.

374. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16:615-619.

375. Muzyk AJ, Jakel RJ, Preud’homme X. Serotonin syndrome after a massive overdose of controlled-release paroxetine. Psychosomatics. 2010;51:437-442.

376. Plowman DM, Reynolds TL, Joyce SM. Poisonous snakebite in Utah. West J Med. 1995;163:547-551.

377. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med. 2002;347:347-356.

378. Lewis JV, Portera CA Jr. Rattlesnake bite of the face: case report and review of the literature. Am Surg. 1994;60:681-682.

379. Stewart RM, Page CP, Schwesinger WH, et al. Antivenin and fasciotomy/debridement in the treatment of the severe rattle-snake bite. Am J Surg. 1989;158:543-547.

380. Schaeffer RC Jr, Carlson RW, Puri VK, et al. The effects of col-loidal and crystalloidal fluids on rattlesnake venom shock in the rat. J Pharmacol Exp Ther. 1978;206:687-695.

381. Saucier JR. Arachnid envenomation. Emerg Med Clin North Am. 2004;22:405-422, ix.

Section11-O-Ref.indd 10 12/10/2014 8:08:26 PM

Chapter 125

REFERENCES

1. Bodenham A, Shelly MP, Park GR. The altered pharmacokinet-ics and pharmacodynamics of drugs commonly used in criti-cally ill patients. Clin Pharmacokinet. 1988;14:347.

2. Nightingale CH, Carver P. Basic principles of pharmacokinetics. Clin Lab Med. 1987;7:267.

3. Winter ME. Basic principles. In: Koda-Kimble MA, Young LY, eds. Basic Clinical Pharmacokinetics. 3rd ed. Vancouver, WA: Applied Therapeutics; 1994:12.

4. Rowland M, Tozer TN. Clinical Pharamcokinetics: Concepts and Applications. 3rd ed. Philadelphia, PA: Lea and Febiger, 1995:35.

5. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hard-man JG, Gilman AG, Limbird LI, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:3.

6. Pratt WB. The entry, distribution, and elimination of drugs. In: Pratt WB, Taylor P, eds. Principles of Drug Action. 3rd ed. New York: Churchill Livingstone; 1990:231-236.

7. Neubig RR. The time course of drug action. In: Pratt WB, Taylor P, eds. Principles of Drug Action. 3rd ed. New York: Churchill Livingstone; 1990:48.

8. Pond SM, Tozer TN. First-pass elimination: basic concepts and clinical consequences. Clin Pharmacokinet. 1984;9:1.

9. Gibaldi M, Koup JR. Pharmacokinetic concepts—drug bind-ing, apparent volume of distribution and clearance. Eur J Clin Pharmacol. 1981;20:299.

10. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to dtubocurarine. Clin Pharmacol Ther. 1979;25:358.

11. Stargel WW, Shand DG, Routledge PA, et al. Clinical com-parison of rapid infusion and multiple injection methods for lidocaine loading. Am Heart J. 1991;102:872.

12. Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther. 1978;23:371.

13. Zhou H-H, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response: altered sensitivity to and clearance of pro-panolol in men of Chinese descent as compared to American whites. N Engl J Med. 1989;320:565.

14. Lang CC, Stein CM, Brown RM, et al. Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med. 1995;333:155.

15. Weinshilboum R. Genomic medicine: inheritance and drug response. N Engl J Med. 2003;348:529.

16. Wang L, McLeod H, Weinshilboum R. Genomics and drug response. N Engl J Med. 2011;364:1144-1153.

17. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.

18. National Institute of Health Pharmacogenetics Research Network’s PharmGKB: The Pharmacogenetics and the Pharmacogenomics Knowledge Base. www.pharmgkb.org. Accessed November 9, 2014.

19. Perazella MA. Drug use and nephrotoxicity in the intensive care unit. Kidney Int. 81:1172-1178.

20. Matzke GR, Aronoff GR, Atkinson AJ et al. Drug dosing consid-eration in patients with acute and chronic kidney disease-a clin-ical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122-1137.

21. Murray P, Wylam ME. Dopamine, dobutamine, and dopexamine. In: Leff AR, ed. Pulmonary and Critical Care Pharmacology and Therapeutics. New York: McGraw-Hill; 1996:239-250.

22. Martin SJ, Danziger LH. Continuous infusion of loop diuret-ics in the critically ill: a review of the literature. Crit Care Med. 1994;22:1323.

23. Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics in chronic renal insufficiency: a continuous infusion is more effi-cacious than bolus therapy. Ann Intern Med. 1991;115:360.

24. Kress JP, O’Connor MF, Pohlman AS, et al. Sedation of critically ill patients during mechanical ventilation: a comparison of pro-pofol and midazolam. Am J Respir Crit Care Med. 1996;153:1012.

25. Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med. 1994;22:1241.

26. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interrup-tion of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342:1471.

27. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830.

28. Rabito CA, Panico F, Rubin R, et al. Noninvasive, real-time monitoring of renal function during critical care. J Am Soc Nephrol. 1994;4:1421.

29. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31.

Section11-O-Ref.indd 1 12/10/2014 8:08:26 PM

References2

30. Gault MH, Longerich LL, Harnett JD, Weslowski C. Predicting glomerular function from adjusted creatinine. Nephron. 1992;62:249.

31. Luke DR, Halstenson CE, Opsahl JA, Matzke GR. Validity of creatinine clearance estimates in the assessment of renal func-tion. Clin Pharmacol Ther. 1990;48:503.

32. Lindeman RD. Assessment of renal function in the old: special considerations. Clin Lab Med. 1993;13:269.

33. Ducharme MP, Smythe M, Strohs G. Drug-induced altera-tions in serum creatinine concentrations. Ann Pharmacother. 1993;27:622.

34. Stevens LA. Measured GFR as a confirmatory test for estimated GFR. J AM Soc Nephrol. 2009;20:2305-2313.

35. Martin C, Alaya M, Bras J, et al. Assessment of creatinine clear-ance in intensive care patients. Crit Care Med. 1990;18:1224.

36. Robert S, Zarowitz BJ. Is there a reliable index of glomerular filtra-tion rate in critically ill patients? Ann Pharmacother. 1991;25:169.

37. Robert S, Zarowitz BJ, Peterson EL, Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med. 1993;21:1487.

38. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461.

39. Stevens LA comparative performance of the CKD epidemiology collaboration (CKD_EPI) and the modification of diet in renal disease (MDRD) Study equations for estimating GFR above 60ml/min. Am J Kidney Dis. 2010;56:486.

40. Zarowitz BJ, Robert S, Peterson EL. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother. 1992;26:1205.

41. Brater DC. Dosing regimens in renal disease. In: Jacobson HE, Striker GA, Klahr S, eds. The Principles and Practice of Nephrology. 2nd ed. St Louis, MO: Mosby-Year Book; 1995:15.

42. Bennett WM, Aronoff GR, Golper TA, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 3rd ed. Philadelphia, PA: American College of Physicians; 1994:38.

43. Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure. West J Med. 1992;156:633.

44. Shuler C, Golper TA, Bennett WM. Prescribing drugs in renal disease. In: Brenner BM, ed. The Kidney. 5th ed. Philadelphia, PA:Saunders; 1996:51.

45. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42:906-925.

46. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacoki-netics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther. 1991;50:688.

47. Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal fail-ure treated with continuous hemofiltration. Am J Kidney Dis. 1993;21:172.

48. Wrighton SA, Stevens JC. The human hepatic cytochromes p450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1.

49. Tukey RH, Johnson EF. Molecular aspects of regulation and structures of the drug-metabolizing enzymes. In: Pratt WB, Taylor P, eds. Principles of Drug Action. 3rd ed. New York: Churchill Livingstone; 1990:56.

50. Watkins PB. Drug metabolism by cytochromes p450 in the liver and small bowel. Gastroenterol Clin North Am. 1992;21:511.

51. Spinler SA, Cheng JWM, Kindwall KE, Charland SL. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther. 1995;57:89.

52. Nelson DR. Cytochrome P450 Homepage. Hum Genomics. 2009;4(1):59-65.

53. Danielson PB. The cytochrome P450 superfamily: biochem-istry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3:561-597.

54. Alvares AP, Pratt WB. Pathways of drug metabolism. In: Pratt WB, Taylor P, eds. Principles of Drug Action. 3rd ed. New York: Churchill Livingstone; 1990:40.

55. OMalley K, Crooks J, Duke E, Stevenson IH. Effect of age and sex on human drug metabolism. Br Med J. 1971;3:607.

56. Masimirembwa CM, Beke M, Hasler JA, et al. Low CYP 1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther. 1995;57:25.

57. May DG, Porter GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther. 1994;55:492.

58. Lown K, Kolars J, Turgeon K, et al. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992;51:229.

59. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther. 1995;57:16.

60. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275.

61. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES Jr, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differneces. Pharmacotherapy. 1998;18:288.

62. Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmcol. 1997;43:579.

63. Loi CM, Parker BM, Cusack B, Vestal RE. Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in helathy male and female nonsmokers. J Pharmacol Exp Ther. 1997;280:627.

64. Reigner BG, Welker HA. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. Antimicrob Agents Chemother. 1996;40:575.

65. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1994;55:509.

66. Lennard MS. Genetically determined adverse drug reactions involving metabolism. Drug Safety. 1993;9:60.

67. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol. 1994;46(suppl 1):417.

68. Vessel ES. Therapeutic lessons from pharmacogenetics. Ann Intern Med. 1997;126:653.

69. Nebert DW, Weber WW. Pharmacogenetics. In Pratt WB, Taylor P eds. Principles of Drug Action. 3rd ed. New York: Churchill Livingstone; 1990:60.

Section11-O-Ref.indd 2 12/10/2014 8:08:26 PM

References 3

70. Tseng C-Y, Wang S-L, Lai M-D, et al. Formation of morphine from codeine in Chinese subjects of different CYP2D6 geno-types. Clin Pharmacol Ther. 1996;60:177.

71. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolism phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991;50:308.

72. Flockhart DA. Drug interactions and the cytochrome p450 system: the role of cytochrome p450 2C19. Clin Pharmacokinet. 1995;29:45.

73. Lerena AL, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992;14:92.

74. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta- analysis. JAMA. 2010;304:1821.

75. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.

76. Daly AK. Significance of Minor Cyt P450 3a Isoforms. Clin Pharmacokinetic. 2006;45:13-31.

77. Evans WE, McLeod HL. Drug therapy: pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538.

78. Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopu-rine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985.

79. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-geno-type correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14:407.

80. Keogh A, Spratt P, McCosker C, et al. Ketoconazole reduces the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995;333:628.

81. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58:15.

82. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of gluc-uronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997;39:440.

83. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharma-codynamic considerations in patients with liver disease. Clin Pharmacokinet. 1995;29:370.

84. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet. 1992;23:132.

85. Verbeeck RK, Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147.

86. Huet P-M, Villeneuve J-P. Determinants of drug disposition in patients with cirrhosis. Hepatology. 1983;3:913.

87. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377.

88. Orlando R, Mussap M, Plebani M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration

marker in decompensated liver cirrhosis. Clin Chem. 2002; 48:850-858.

89. Schentag JJ, Cerra FB, Calleri GM, et al. Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther. 1981;29:737.

90. Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clin Pharmacokinet. 1988;15:396.

91. Rudy AC, Brater DC. Drug interactions. In: Chernow B, ed. The Pharmacologic Approach to the Critically Ill Patient. 3rd ed. Baltimore, MD: Williams & Wilkins; 1994:15.

92. Wright JM. Drug interactions. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Melmon and Morrelli’s Clinical Pharmacology: Basic Principles in Therapeutics. 3rd ed. New York: McGraw-Hill; 1992:21.

93. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporine by the gut. Lancet. 1991; 338:1488.

94. MacKichan JJ. Protein binding drug displacement interactions: fact or fiction? Clin Pharmacokinet. 1989;16:65.

95. Kaplan B, Friedman G, Jacobs M, et al. Potential interac-tions of troglitazone and cyclosporine. Transplantation. 1998; 65:1399.

96. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predis-posing to statin-induced myopathy. Drug Safety. 2010;33(3): 171-187.

97. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA. 1996;275:1339.

98. Pearson TF, Pittman DG, Longley JM, et al. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm. 1994;51:2268.

99. Wood AJJ. Adverse reactions to drugs. In: Isselbacher KJ, Braunwald E, Wilson JD, et al. eds. Harrison’s Principles of Internal Medicine. 13th ed. New York: McGraw-Hill; 1994:25.

100. Cox ZL. Adverse drug events during AKI and its recovery. Clin J Am Soc Nephrol. 2013;8:1070-1078.

101. Cribb AE, Lee BL, Trepanier LA, Speilberg SP. Adverse reac-tions to sulphonamide and sulphonamide-trimethoprim anti-microbials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 1996;15:9.

102. Rieder MJ. Immunopharmacology and adverse drug reactions. J Clin Pharmacol. 1993;33:316.

103. Amstutz U Ross CJ, Castro-Pastrana LI, et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensi-tivity in children. Clin Pharmacol Ther. 2013;94:142.

104. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.

105. Bonfiglio MF, Traeger SM, Kier KL, et al. Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother. 1995;29:835.

106. Krishnan V, Corbridge T, Murray P. Critical care pharmacology. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care. 3rd ed. New York: McGraw-Hill; 2005:1547.

107. Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med. 2003;348:2526.

108. Pronovost PJ, Waters H, Dorman T. Impact of critical care phy-sician workforce for intensive care unit physician staffing. Curr Opin Critical Care. 2001;7:456.

Section11-O-Ref.indd 3 12/10/2014 8:08:27 PM

References4

109. Goh AY, Lum LC, Abdel-Latif ME. Impact of 24 hour critical care physician staffing on case-mix adjusted mortality in paedi-atric intensive care. Lancet. 2001;357:445.

110. Shaprio JP. Industry preaches safety in Pittsburgh. US News World Rep. 2000;56.

111. Anderson JG, Jay SJ, Anderson M, Hunt TJ. Evaluating the capability of information technology to prevent adverse drug events: a computer simulation approach. J Am Med Inform Assoc. 2002;9:479.

112. Kopp BJ, cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64;2483-2487.

113. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc. 2008;15(5):585-600.

Section11-O-Ref.indd 4 12/10/2014 8:08:27 PM

Chapter 126

REFERENCES

1. Janssen NM, Karnad DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Crit Care Clin. October 2002;18(4):729-748.

2. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythe-matosus: clinical and immunologic patterns of disease expres-sion in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). March 1993;72(2):113-124.

3. Inoue T, Takeda T, Koda S, et al. Differential diagnosis of fever in systemic lupus erythematosus using discriminant analysis. Rheumatol Int. 1986;6(2):69-77.

4. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum. April 1996;25(5):318-336.

5. Boumpas DT, Austin HA III, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pul-monary, and hematologic disease. Ann Intern Med. June 15, 1995;122(12):940-950.

6. Ponticelli C, Moroni G. Renal transplantation in lupus nephri-tis. Lupus. 2005;14(1):95-98.

7. Kamen DL, Strange C. Pulmonary manifestations of sys-temic lupus erythematosus. Clin Chest Med. September 2010;31(3):479-488.

8. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and man-agement of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. June 2010;6(6):358-367.

9. Widener HL, Littman BH. Ibuprofen-induced meningitis in systemic lupus erythematosus. Jama. March 13, 1978;239(11): 1062-1064.

10. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. February 2000;59(2):120-124.

11. Kur JK, Esdaile JM. Posterior reversible encephalopathy syndrome—an underrecognized manifestation of systemic lupus erythematosus. J Rheumatol. November 2006;33(11):2178-2183.

12. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. May 4, 2006;354(18):1927-1935.

13. Hant FN, Herpel LB, Silver RM. Pulmonary manifestations of scleroderma and mixed connective tissue disease. Clin Chest Med. September 2010;31(3):433-449.

14. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. May 2003;29(2):315-333.

15. Guillevin L, Berezne A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford). 2012;51(3):460-467.

16. Hesselstrand R, Scheja A, Wuttge D. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol. February 2012;41(1):39-43.

17. Rhew EY, Barr WG. Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep. April 2004;6(2):129-136.

18. Dhaun N, MacIntyre IM, Bellamy CO, Kluth DC. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis. October 2009;54(4):726-731.

19. Marinelli WA, Leatherman JW. Neuromuscular disorders in the intensive care unit. Crit Care Clin. October 2002;18(4): 915-929, x.

20. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. September 20, 2003;362(9388):971-982.

21. Edwards RH, Round JM, Jones DA. Needle biopsy of skel-etal muscle: a review of 10 years experience. Muscle Nerve. November-December 1983;6(9):676-683.

22. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med. August 2007;28(4):451-458.

23. Aggarwal R, Oddis CV. Therapeutic approaches in myositis. Curr Rheumatol Rep. June 2011;13(3):182-191.

24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). February 2004;43(2):143-147.

25. Neva MH, Kauppi MJ, Kautiainen H, et al. Combination drug therapy retards the development of rheumatoid atlantoaxial sub-luxations. Arthritis Rheum. November 2000;43(11):2397-2401.

26. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic dis-eases. Ann N Y Acad Sci. December 2009;1182:111-123.

27. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory dis-eases and implications for common illnesses. J Allergy Clin Immunol. December 2009;124(6):1141-1149; quiz 1141-1151.

28. Godeau B, Mortier E, Roy PM, et al. Short and longterm out-comes for patients with systemic rheumatic diseases admitted

Section11-O-Ref.indd 1 12/10/2014 8:08:27 PM

References2

to intensive care units: a prognostic study of 181 patients. J Rheumatol. July 1997;24(7):1317-1323.

29. Pourrat O, Bureau JM, Hira M, Martin-Barbaz F, Descamps JM, Robert R. Outcome of patients with systemic rheumatic diseases admitted to intensive care units: a retrospective study of 39 cases. Rev Med Interne. February 2000;21(2):147-151.

30. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. October 2008;22(5):773-792.

31. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol. August 2009;37(1):20-28.

32. Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclero-sis in patients with rheumatoid arthritis. Arthritis Res Ther. 2006;8(6):R186.

33. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683-686.

34. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. July 19, 2008;372(9634):234-245.

35. Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). March 2005;84(2):115-128.

36. Passam FH, Diamantis ID, Perisinaki G, et al. Intestinal isch-emia as the first manifestation of vasculitis. Semin Arthritis Rheum. August 2004;34(1):431-441.

37. Ahn E, Luk A, Chetty R, Butany J. Vasculitides of the gastroin-testinal tract. Semin Diagn Pathol. May 2009;26(2):77-88.

38. Peto P, Salama AD. Update on antiglomerular basement mem-brane disease. Curr Opin Rheumatol. January 2011;23(1):32-37.

39. Dweik RA, Arroliga AC, Cash JM. Alveolar hemorrhage in patients with rheumatic disease. Rheum Dis Clin North Am. May 1997;23(2):395-410.

40. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. October 2002;61(10):922-924.

41. Gomez-Puerta JA, Hernandez-Rodriguez J, Lopez-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vas-culitides and respiratory disease. Chest. October 2009;136(4): 1101-1111.

42. Zoysa J, Taylor D, Thein H, Yehia M. Incidence and fea-tures of dual anti-GBM-positive and ANCA-positive patients. Nephrology (Carlton). November 2011;16(8):725-729.

43. Hajj-Ali RA, Singhal AB, Benseler S, Molloy E, Calabrese LH. Primary angiitis of the CNS. Lancet Neurol. June 2011;10(6): 561-572.

44. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation. August 10, 2010;122(6):631-641.

45. Bowles CA. Vasculopathy associated with the antiphospho-lipid antibody syndrome. Rheum Dis Clin North Am. May 1990;16(2):471-490.

46. Joyce JW. Buerger’s disease (thromboangiitis obliterans). Rheum Dis Clin North Am. May 1990;16(2):463-470.

47. Bathon J, Graves J, Jens P, Hamrick R, Mayes M. The erythro-cyte sedimentation rate in end-stage renal failure. Am J Kidney Dis. July 1987;10(1):34-40.

48. Connelly CS, Panush RS. Markedly Elevatated Sedimentation Rates: What Is Their Clinical Significance? Vol. IV. Berryville, Virginia: Forum Medicum, Inc.; 1990.

49. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. September 1997;40(9):1601-1611.

50. Li QZ, Karp DR, Quan J, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011;13(2):R38.

51. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guide-lines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. August 2002;47(4):434-444.

52. Catoggio LJ, Bernstein RM, Black CM, Hughes GR, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis. February 1983;42(1):23-27.

53. Chorzelski TP, Jablonska S, Beutner EH, et al. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermatol. October 1985;113(4):381-389.

54. Harmon CE. Antinuclear antibodies in autoimmune disease. Significance and pathogenicity. Med Clin North Am. May 1985;69(3):547-563.

55. Moder KG. Use and interpretation of rheumatologic tests: a guide for clinicians. Mayo Clin Proc. April 1996;71(4):391-396.

56. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. March 2009;5(3):139-148.

57. Buyon JP, Rupel A, Clancy RM. Neonatal lupus syndromes. Lupus. 2004;13(9):705-712.

58. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH. Scl 70 antibody—a specific marker of systemic sclerosis. Br J Dermatol. October 1986;115(4):393-401.

59. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoanti-bodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. June 23 1988;318(25):1651-1657.

60. Schnabel A, Hauschild S, Gross WL. Anti-neutrophil cytoplas-mic antibodies in generalized autoimmune diseases. Int Arch Allergy Immunol. March 1996;109(3):201-206.

61. Specks U, DeRemee RA. Granulomatous vasculitis. Wegener’s granulomatosis and Churg-Strauss syndrome. Rheum Dis Clin North Am. May 1990;16(2):377-397.

62. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol. May 2004;16(3):246-253.

63. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diag-nostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. June 5, 2007;146(11):797-808.

64. Luban S, Li ZG. Citrullinated peptide and its relevance to rheumatoid arthritis: an update. Int J Rheum Dis. October 2010;13(4):284-287.

65. Chen M, Daha MR, Kallenberg CG. The complement sys-tem in systemic autoimmune disease. J Autoimmun. May 2010;34(3):J276-J286.

Section11-O-Ref.indd 2 12/10/2014 8:08:27 PM

References 3

66. George D, Erkan D. Antiphospholipid syndrome. Prog Cardiovasc Dis. September-October 2009;52(2):115-125.

67. Westney GE, Harris EN. Catastrophic antiphospholipid syndrome in the intensive care unit. Crit Care Clin. October 2002;18(4):805-817.

68. Asherson RA. The catastrophic antiphospholipid (Asherson’s) syndrome. Autoimmun Rev. December 2006;6(2):64-67.

69. Sahn SA, Lakshminarayan S. Tuberculosis after corticosteroid therapy. Br J Dis Chest. July 1976;70(3):195-205.

70. Iseman MD. Tuberculosis prophylaxis during corticosteroid therapy. JAMA. July 10, 1987;258(2):263-264.

71. Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg. April 1994;219(4):416-425.

72. Meyer NJ, Hall JB. Relative adrenal insufficiency in the ICU: can we at least make the diagnosis? Am J Respir Crit Care Med. December 15, 2006;174(12):1282-1284.

73. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. January 1990;33(1):9-18.

74. Kazatchkine MD, Kaveri SV. Immunomodulation of autoim-mune and inflammatory diseases with intravenous immune globulin. N Engl J Med. September 6, 2001;345(10):747-755.

75. NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. Jama. December 26, 1990; 264(24):3189-3193.

76. Curtis JR, Singh JA. Use of biologics in rheumatoid arthri-tis: current and emerging paradigms of care. Clin Ther. June 2011;33(6):679-707.

77. Johnson PW, Glennie MJ. Rituximab: mechanisms and applica-tions. Br J Cancer. November 30, 2001;85(11):1619-1623.

78. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol. May 2011;23(3): 245-251.

79. Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22(5):712-719.

80. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. September 2010;22(5): 504-509.

81. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. February 26, 2011;377(9767):721-731.

82. Nguyen TC, Kiss JE, Goldman JR, Carcillo JA. The role of plasmapheresis in critical illness. Crit Care Clin. July 2012;28(3): 453-468, vii.

83. Casian A, Jayne D. Plasma exchange in the treatment of Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol. January 2011;23(1):12-17.

Section11-O-Ref.indd 3 12/10/2014 8:08:27 PM

Chapter 127

REFERENCES

1. Rizk NW, Kalassian KG, Gilligan T, Druzin MI, Daniel DL. Obstetric complications in pulmonary and critical care medi-cine. Chest. September 1996;110(3):791-809.

2. Sullivan JM, Ramanathan KB. Management of medical prob-lems in pregnancy—severe cardiac disease. N Engl J Med. August 1 1985;313(5):304-309.

3. Lapinsky SE, Kruczynski K, Slutsky AS. Critical care in the pregnant patient. Am J Respir Crit Care Med. August 1995;152(2):427-455.

4. Capeless EL, Clapp JF. Cardiovascular changes in early phase of pregnancy. Am J Obstet Gynecol. December 1989;161 (6 Pt 1):1449-1453.

5. Mabie WC, DiSessa TG, Crocker LG, Sibai BM, Arheart KL. A longitudinal study of cardiac output in normal human preg-nancy. Am J Obstet Gynecol. March 1994;170(3):849-856.

6. Mesa A, Jessurun C, Hernandez A, et al. Left ventricular diastolic function in normal human pregnancy. Circulation. February 2, 1999;99(4):511-517.

7. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. April 1989;256(4 Pt 2):H1060-H1065.

8. Mone SM, Sanders SP, Colan SD. Control mechanisms for physiological hypertrophy of pregnancy. Circulation. August 15, 1996;94(4):667-672.

9. Barron WM, Murphy BM, Lindheimer MD. Management of Hypertension during Pregnancy. Hypertension: Pathophysiology, Diagnosis, and Management. New York: Raven; 1990.

10. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. July 2000;183(1):S1-S22.

11. Clark SL, Cotton DB, Lee W, et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol. December 1989;161(6 Pt 1):1439-1442.

12. Weinberger SE, Weiss ST, Cohen WR, Weiss JW, Johnson TS. Pregnancy and the lung. Am Rev Respir Dis. March 1980;121(3):559-581.

13. Pernoll ML, Metcalfe J, Schlenker TL, Welch JE, Matsumoto JA. Oxygen consumption at rest and during exercise in pregnancy. Respir Physiol. December 1975;25(3):285-293.

14. Rees GB, Broughton Pipkin F, Symonds EM, Patrick JM. A longitudinal study of respiratory changes in normal human pregnancy with cross-sectional data on subjects with

pregnancy-induced hypertension. Am J Obstet Gynecol. March 1990;162(3):826-830.

15. Cugell DW, Frank NR, Gaensler EA, Badger TL. Pulmonary function in pregnancy. I. Serial observations in normal women. Am Rev Tuberc. May 1953;67(5):568-597.

16. Awe RJ, Nicotra MB, Newsom TD, Viles R. Arterial oxygen-ation and alveolar-arterial gradients in term pregnancy. Obstet Gynecol. February 1979;53(2):182-186.

17. Elkus R, Popovich J, Jr. Respiratory physiology in pregnancy. Clin Chest Med. December 1992;13(4):555-565.

18. Craig DB, Toole MA. Airway closure in pregnancy. Can Anaesth Soc J. November 1975;22(6):665-672.

19. Baldwin GR, Moorthi DS, Whelton JA, MacDonnell KF. New lung functions and pregnancy. Am J Obstet Gynecol. February 1, 1977;127(3):235-239.

20. Dafnis E, Sabatini S. The effect of pregnancy on renal func-tion: physiology and pathophysiology. Am J Med Sci. March 1992;303(3):184-205.

21. Van Thiel DH, Gavaler JS, Joshi SN, Sara RK, Stremple J. Heartburn of pregnancy. Gastroenterology. April 1977;72(4 Pt 1):666-668.

22. Assali NS. Dynamics of the uteroplacental circulation in health and disease. Am J Perinatol. April 1989;6(2):105-109.

23. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mor-tality surveillance—United States, 1991–1999. MMWR Surveill Summ. February 21, 2003;52(2):1-8.

24. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. December 2010;116(6):1302-1309.

25. Vasquez DN, Estenssoro E, Canales HS, et al. Clinical character-istics and outcomes of obstetric patients requiring ICU admis-sion. Chest. March 2007;131(3):718-724.

26. Belfort MA, Rokey R, Saade GR, Moise KJ, Jr. Rapid echocar-diographic assessment of left and right heart hemodynamics in critically ill obstetric patients. Am J Obstet Gynecol. October 1994;171(4):884-892.

27. Nolan TE, Wakefield ML, Devoe LD. Invasive hemodynamic monitoring in obstetrics. A critical review of its indica-tions, benefits, complications, and alternatives. Chest. May 1992;101(5):1429-1433.

28. Bouwmeester FW, Bolte AC, van Geijn HP. Pharmacological and surgical therapy for primary postpartum hemorrhage. Curr Pharm Des. 2005;11(6):759-773.

Section11-O-Ref.indd 1 12/10/2014 8:08:28 PM

References2

29. Hazelgrove JF, Price C, Pappachan VJ, Smith GB. Multicenter study of obstetric admissions to 14 intensive care units in south-ern England. Crit Care Med. April 2001;29(4):770-775.

30. Wise A, Clark V. Strategies to manage major obstetric haemor-rhage. Curr Opin Anaesthesiol. June 2008;21(3):281-287.

31. Mercier FJ, Van de Velde M. Major obstetric hemorrhage. Anesthesiol Clin. March 2008;26(1):53-66, vi.

32. Naeye RL. Abruptio placentae and placenta previa: frequency, perinatal mortality, and cigarette smoking. Obstet Gynecol. June 1980;55(6):701-704.

33. Hayashi RH. Hemorrhagic shock in obstetrics. Clin Perinatol. December 1986;13(4):755-763.

34. Finley BE. Acute coagulopathy in pregnancy. Med Clin North Am. May 1989;73(3):723-743.

35. Slutsker L. Risks associated with cocaine use during pregnancy. Obstet Gynecol. May 1992;79(5 Pt 1):778-789.

36. Roberts WE. Emergent obstetric management of post-partum hemorrhage. Obstet Gynecol Clin North Am. June 1995;22(2):283-302.

37. Dow M, Wax JR, Pinette MG, Blackstone J, Cartin A. Third-trimester uterine rupture without previous cesarean: a case series and review of the literature. Am J Perinatol. November 2009;26(10):739-744.

38. Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiol-ogy, risk factors, and causes. Clin Obstet Gynecol. March 2010;53(1):147-156.

39. Anderson JM, Etches D. Prevention and management of postpartum hemorrhage. Am Fam Physician. March 15, 2007;75(6):875-882.

40. Montagnana M, Franchi M, Danese E, Gotsch F, Guidi GC. Disseminated intravascular coagulation in obstetric and gyne-cologic disorders. Semin Thromb Hemost. June 2010;36(4):404-418.

41. Ahonen J, Stefanovic V, Lassila R. Management of post-partum haemorrhage. Acta Anaesthesiol Scand. November 2010;54(10):1164-1178.

42. Mercier FJ, Bonnet MP. Use of clotting factors and other prohemostatic drugs for obstetric hemorrhage. Curr Opin Anaesthesiol. June 2010;23(3):310-316.

43. Ramanathan G, Arulkumaran S. Postpartum hemorrhage. J Obstet Gynaecol Can. November 2006;28(11):967-973.

44. Rossi AC, Lee RH, Chmait RH. Emergency postpartum hys-terectomy for uncontrolled postpartum bleeding: a systematic review. Obstet Gynecol. March 2010;115(3):637-644.

45. El-Kady D, Gilbert WM, Anderson J, Danielsen B, Towner D, Smith LH. Trauma during pregnancy: an analysis of maternal and fetal outcomes in a large population. Am J Obstet Gynecol. June 2004;190(6):1661-1668.

46. Chames MC, Pearlman MD. Trauma during pregnancy: out-comes and clinical management. Clin Obstet Gynecol. June 2008;51(2):398-408.

47. Weiss HB, Songer TJ, Fabio A. Fetal deaths related to maternal injury. JAMA. October 17 2001;286(15):1863-1868.

48. Curet MJ, Schermer CR, Demarest GB, Bieneik EJ III, Curet LB. Predictors of outcome in trauma during pregnancy: identifica-tion of patients who can be monitored for less than 6 hours. J Trauma. July 2000;49(1):18-24; discussion 24-15.

49. Rogers FB, Rozycki GS, Osler TM, et al. A multi-institutional study of factors associated with fetal death in injured pregnant patients. Arch Surg. November 1999;134(11):1274-1277.

50. Pearlman MD, Tintinalli JE, Lorenz RP. Blunt trauma during pregnancy. N Engl J Med. December 6, 1990;323(23):1609-1613.

51. Hayes B, Ryan S, Stephenson JB, King MD. Cerebral palsy after maternal trauma in pregnancy. Dev Med Child Neurol. September 2007;49(9):700-706.

52. Richards JR, Ormsby EL, Romo MV, Gillen MA, McGahan JP. Blunt abdominal injury in the pregnant patient: detection with US. Radiology. November 2004;233(2):463-470.

53. Weber CE. Postmortem cesarean section: review of the literature and case reports. Am J Obstet Gynecol. May 15, 1971;110(2):158-165.

54. Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE, Landzberg MJ. Pregnancy outcomes in women with congenital heart disease. Circulation. January 31, 2006;113(4): 517-524.

55. Reimold SC, Rutherford JD. Clinical practice. Valvular heart disease in pregnancy. N Engl J Med. July 3, 2003;349(1):52-59.

56. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. July 31, 2001;104(5):515-521.

57. Lane CR, Trow TK. Pregnancy and pulmonary hypertension. Clin Chest Med. March 2011;32(1):165-174, x.

58. Nahapetian A, Oudiz RJ. Serial hemodynamics and complica-tions of pregnancy in severe pulmonary arterial hypertension. Cardiology. 2008;109(4):237-240.

59. Bourjeily G, Miller M. Obstetric disorders in the ICU. Clin Chest Med. March 2009;30(1):89-102, viii.

60. de Beus E, van Mook WN, Ramsay G, Stappers JL, van der Putten HW. Peripartum cardiomyopathy: a condition inten-sivists should be aware of. Intensive Care Med. February 2003;29(2):167-174.

61. Expert consensus document on management of cardiovascu-lar diseases during pregnancy. Eur Heart J. April 2003;24(8): 761-781.

62. Murali S, Baldisseri MR. Peripartum cardiomyopathy. Crit Care Med. October 2005;33(suppl 10):S340-S346.

63. Mabie WC, Freire CM. Sudden chest pain and cardiac emer-gencies in the obstetric patient. Obstet Gynecol Clin North Am. March 1995;22(1):19-37.

64. Nallamothu BK, Saint M, Saint S, Mukherjee D. Clinical problem-solving. Double jeopardy. N Engl J Med. July 7, 2005;353(1):75-80.

65. Cox SM, Hankins GD, Leveno KJ, Cunningham FG. Bacterial endocarditis. A serious pregnancy complication. J Reprod Med. July 1988;33(7):671-674.

66. Kiely DG, Condliffe R, Webster V, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofes-sional approach. BJOG. April 2010;117(5):565-574.

67. James AH, Jamison MG, Biswas MS, Brancazio LR, Swamy GK, Myers ER. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation. March 28, 2006;113(12):1564-1571.

68. Kealey A. Coronary artery disease and myocardial infarc-tion in pregnancy: a review of epidemiology, diagnosis, and

Section11-O-Ref.indd 2 12/10/2014 8:08:28 PM

References 3

medical and surgical management. Can J Cardiol. June-July 2010;26(6):185-189.

69. Fernandez-Perez ER, Salman S, Pendem S, Farmer JC. Sepsis during pregnancy. Crit Care Med. October 2005;33(suppl 10):S286-S293.

70. Lee W, Clark SL, Cotton DB, et al. Septic shock during preg-nancy. Am J Obstet Gynecol. August 1988;159(2):410-416.

71. Naylor DF Jr, Olson MM. Critical care obstetrics and gynecol-ogy. Crit Care Clin. January 2003;19(1):127-149.

72. Fein AM, Duvivier R. Sepsis in pregnancy. Clin Chest Med. December 1992;13(4):709-722.

73. Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syn-drome associated with Clostridium sordellii after medical abor-tion. N Engl J Med. December 1, 2005;353(22):2352-2360.

74. Stubblefield PG, Grimes DA. Septic abortion. N Engl J Med. August 4, 1994;331(5):310-314.

75. Rahangdale L. Infectious complications of pregnancy termina-tion. Clin Obstet Gynecol. June 2009;52(2):198-204.

76. Tita AT, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol. June 2010;37(2):339-354.

77. Aronoff DM, Mulla ZD; Postpartum Invasive Group. A strep-tococcal disease in the modern era. Infect Dis Obstet Gynecol. 2008;2008:796892.

78. de Moya MA, del Carmen MG, Allain RM, Hirschberg RE, Shepard JA, Kradin RL. Case records of the Massachusetts General Hospital. Case 33-2009. A 35-year-old woman with fever, abdominal pain, and hypotension after cesarean section. N Engl J Med. October 22, 2009;361(17):1689-1697.

79. Hill JB, Sheffield JS, McIntire DD, Wendel GD Jr. Acute pyelone-phritis in pregnancy. Obstet Gynecol. January 2005;105(1):18-23.

80. Janakiraman V. Listeriosis in pregnancy: diagnosis, treatment, and prevention. Rev Obstet Gynecol. Fall 2008;1(4):179-185.

81. Guinn DA, Abel DE, Tomlinson MW. Early goal directed therapy for sepsis during pregnancy. Obstet Gynecol Clin North Am. September 2007;34(3):459-479, xi.

82. Feissel M, Michard F, Faller JP, Teboul JL. The respiratory varia-tion in inferior vena cava diameter as a guide to fluid therapy. Intensive Care Med. September 2004;30(9):1834-1837.

83. Barbier C, Loubieres Y, Schmit C, et al. Respiratory changes in inferior vena cava diameter are helpful in predicting fluid responsiveness in ventilated septic patients. Intensive Care Med. September 2004;30(9):1740-1746.

84. Neligan PJ, Laffey JG. Clinical review: special populations—critical illness and pregnancy. Crit Care. 2011;15(4):227.

85. Beigi RH. Clinical implications of methicillin-resistant Staphylococcus aureus in pregnancy. Curr Opin Obstet Gynecol. April 2011;23(2):82-86.

86. Kankuri E, Kurki T, Carlson P, Hiilesmaa V. Incidence, treat-ment and outcome of peripartum sepsis. Acta Obstet Gynecol Scand. August 2003;82(8):730-735.

87. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. March 2004;32(3):858-873.

88. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. February 20, 2003;348(8):727-734.

89. Leeman L, Fontaine P. Hypertensive disorders of pregnancy. Am Fam Physician. July 1, 2008;78(1):93-100.

90. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. August 21, 2010;376(9741):631-644.

91. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. March 12, 2005;330(7491):565.

92. Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: Risk fac-tors and causal models. Best Pract Res Clin Obstet Gynaecol. June 2011;25(3):329-342.

93. Karumanchi SA, Lindheimer MD. Advances in the under-standing of eclampsia. Curr Hypertens Rep. August 2008;10(4): 305-312.

94. Hirshfeld-Cytron J, Lam C, Karumanchi SA, Lindheimer M. Late postpartum eclampsia: examples and review. Obstet Gynecol Surv. July 2006;61(7):471-480.

95. Gilson G, Golden P, Izquierdo L, Curet L. Pregnancy-associated hemolysis, elevated liver function, low platelets (HELLP) syn-drome: an obstetric disease in the intensive care unit. J Intensive Care Med. 1996;11:173-192.

96. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of pre-eclampsia. Annu Rev Pathol. 2010;5:173-192.

97. Mabie WC, Ratts TE, Sibai BM. The central hemodynam-ics of severe preeclampsia. Am J Obstet Gynecol. December 1989;161(6 Pt 1):1443-1448.

98. Sibai BM, Mabie BC, Harvey CJ, Gonzalez AR. Pulmonary edema in severe preeclampsia-eclampsia: analysis of thirty-seven con-secutive cases. Am J Obstet Gynecol. May 1987;156(5):1174-1179.

99. Mabie WC, Ratts TE, Ramanathan KB, Sibai BM. Circulatory congestion in obese hypertensive women: a subset of pulmonary edema in pregnancy. Obstet Gynecol. October 1988;72(4):553-558.

100. Hertig A, Liere P. New markers in preeclampsia. Clin Chim Acta. November 11, 2010;411(21-22):1591-1595.

101. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. February 12, 2004;350(7):672-683.

102. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other cir-culating antiangiogenic factors in preeclampsia. N Engl J Med. September 7, 2006;355(10):992-1005.

103. Bushnell C, Chireau M. Preeclampsia and stroke: risks during and after pregnancy. Stroke Res Treat. 2011;2011:858134.

104. Staykov D, Schwab S. Posterior reversible encephalophathy syn-drome. J Intensive Care Med. 2012;27:11-24

105. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a para-digm shift focusing on systolic blood pressure. Obstet Gynecol. February 2005;105(2):246-254.

106. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. April 2008;51(4):960-969.

107. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hyper-tension during pregnancy. Cochrane Database Syst Rev. 2007(1):CD002252.

108. Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010(11):CD000025.

109. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. June 10, 1995;345(8963):1455-1463.

Section11-O-Ref.indd 3 12/10/2014 8:08:28 PM

References4

110. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommi-ttees, American Heart Association. Part IV. Special resuscitation situations. JAMA. October 28, 1992;268(16):2242-2250.

111. Jeejeebhoy FM, Zelop CM, Windrim R, Carvalho JC, Dorian P, Morrison LJ. Management of cardiac arrest in pregnancy: a systematic review. Resuscitation. July 2011;82(7):801-809.

112. Morris S, Stacey M. Resuscitation in pregnancy. BMJ. November 29, 2003;327(7426):1277-1279.

113. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. November 6, 2008;359(19):2025-2033.

114. Leonhardt G, Gaul C, Nietsch HH, Buerke M, Schleussner E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. June 2006;21(3):271-276.

115. DePace NL, Betesh JS, Kotler MN. ‘Postmortem’ cesarean sec-tion with recovery of both mother and offspring. JAMA. August 27, 1982;248(8):971-973.

116. King TE, Jr. Restrictive lung disease in pregnancy. Clin Chest Med. December 1992;13(4):607-622.

117. Hung CT, Pelosi M, Langer A, Harrigan JT. Blood gas measure-ments in the kyphoscoliotic gravida and her fetus: report of a case. Am J Obstet Gynecol. January 15, 1975;121(2):287-289.

118. Deblieux PM, Summer WR. Acute respiratory failure in preg-nancy. Clin Obstet Gynecol. March 1996;39(1):143-152.

119. Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med. March 2011;32(1):93-110, ix.

120. Papiris S, Kotanidou A, Malagari K, Roussos C. Clinical review: severe asthma. Crit Care. February 2002;6(1):30-44.

121. The use of newer asthma and allergy medications during preg-nancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Ann Allergy Asthma Immunol. May 2000;84(5):475-480.

122. Whitty JE. Cystic fibrosis in pregnancy. Clin Obstet Gynecol. June 2010;53(2):369-376.

123. Ciafaloni E, Massey JM. Myasthenia gravis and pregnancy. Neurol Clin. November 2004;22(4):771-782.

124. Plauche WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol. March 1991;34(1):82-99.

125. Budev MM, Arroliga AC, Emery S. Exacerbation of underly-ing pulmonary disease in pregnancy. Crit Care Med. October 2005;33(suppl 10):S313-S318.

126. Rodrigues J, Niederman MS. Pneumonia complicating preg-nancy. Clin Chest Med. December 1992;13(4):679-691.

127. Brito V, Niederman MS. Pneumonia complicating pregnancy. Clin Chest Med. March 2011;32(1):121-132, ix.

128. Pereira A, Krieger BP. Pulmonary complications of pregnancy. Clin Chest Med. June 2004;25(2):299-310.

129. Sridama V, Pacini F, Yang SL, Moawad A, Reilly M, DeGroot LJ. Decreased levels of helper T cells: a possible cause of immuno-deficiency in pregnancy. N Engl J Med. August 5, 1982;307(6): 352-356.

130. Noble PW, Lavee AE, Jacobs MM. Respiratory diseases in preg-nancy. Obstet Gynecol Clin North Am. June 1988;15(2):391-428.

131. Maternal and infant outcomes among severely ill pregnant and post-partum women with 2009 pandemic influenza A (H1N1)—United States, April 2009–August 2010. MMWR Morb Mortal Wkly Rep. September 9, 2011;60:1193-1196.

132. Mangtani P, Mak TK, Pfeifer D. Pandemic H1N1 infec-tion in pregnant women in the USA. Lancet. August 8, 2009;374(9688):429-430.

133. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. August 8, 2009;374(9688):451-458.

134. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)—United States, May-August 2009. MMWR Morb Mortal Wkly Rep. October 2, 2009;58(38):1071-1074.

135. Boggild AK, McGeer AJ. Laboratory diagnosis of 2009 H1N1 influenza A virus. Crit Care Med. April 2010;38(suppl 4):e38-e42.

136. Chehab BM, Fakih RO, Zackula MA, Minns GO. Use of QuantiFERON-TB Gold Assay in pregnant patients. Kansas Journal of Medicine. 2010;3(2):24-30.

137. Vallejo JG, Starke JR. Tuberculosis and pregnancy. Clin Chest Med. December 1992;13(4):693-707.

138. Ahmad H, Mehta NJ, Manikal VM, et al. Pneumocystis carinii pneumonia in pregnancy. Chest. August 2001;120(2):666-671.

139. Crum NF, Ballon-Landa G. Coccidioidomycosis in pregnancy: case report and review of the literature. Am J Med. November 2006;119(11):993-997.

140. Hollingsworth HM, Irwin RS. Acute respiratory failure in preg-nancy. Clin Chest Med. December 1992;13(4):723-740.

141. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. April 21, 2010;303(15):1517-1525.

142. Carlson A, Thung SF, Norwitz ER. H1N1 influenza in preg-nancy: what all obstetric care providers ought to know. Rev Obstet Gynecol. Summer 2009;2(3):139-145.

143. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. February 15, 2003;167(4):603-662.

144. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guideline for the treatment of coc-cidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis. April 2000;30(4):658-661.

145. Baggish MS, Hooper S. Aspiration as a cause of maternal death. Obstet Gynecol. March 1974;43(3):327-336.

146. Pisani RJ, Rosenow EC III. Pulmonary edema associated with tocolytic therapy. Ann Intern Med. May 1, 1989;110(9):714-718.

147. Masson RG. Amniotic fluid embolism. Clin Chest Med. December 1992;13(4):657-665.

148. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. November 2009;201(5):445 e441-e413.

149. Clark SL. Amniotic fluid embolism. Clin Perinatol. December 1986;13(4):801-811.

150. Clark SL, Montz FJ, Phelan JP. Hemodynamic alterations associ-ated with amniotic fluid embolism: a reappraisal. Am J Obstet Gynecol. March 1, 1985;151(5):617-621.

151. Mirski MA, Lele AV, Fitzsimmons L, Toung TJ. Diagnosis and treatment of vascular air embolism. Anesthesiology. January 2007;106(1):164-177.

152. Cole DE, Taylor TL, McCullough DM, Shoff CT, Derdak S. Acute respiratory distress syndrome in pregnancy. Crit Care Med. October 2005;33(suppl 10):S269-S278.

Section11-O-Ref.indd 4 12/10/2014 8:08:28 PM

References 5

153. Campbell LA, Klocke RA. Implications for the pregnant patient. Am J Respir Crit Care Med. April 2001;163(5):1051-1054.

154. Honiden S, Abdel-Razeq SS, Siegel MD. The management of the critically ill obstetric patient. J Intensive Care Med. 2013;28:93-106.

155. Mighty HE. Acute respiratory failure in pregnancy. Clin Obstet Gynecol. June 2010;53(2):360-368.

156. Levinson G, Shnider SM, DeLorimier AA, Steffenson JL. Effects of maternal hyperventilation on uterine blood flow and fetal oxygenation and acid-base status. Anesthesiology. April 1974;40(4):340-347.

157. Bourjeily G, Ankner G, Mohsenin V. Sleep-disordered breath-ing in pregnancy. Clin Chest Med. March 2011;32(1):175-189, x.

158. King TA, Adams AP. Failed tracheal intubation. Br J Anaesth. September 1990;65(3):400-414.

159. Ezri T, Szmuk P, Evron S, Geva D, Hagay Z, Katz J. Difficult airway in obstetric anesthesia: a review. Obstet Gynecol Surv. October 2001;56(10):631-641.

160. Cunningham JA, Devine PC, Jelic S. Extracorporeal mem-brane oxygenation in pregnancy. Obstet Gynecol. September 2006;108(3 Pt 2):792-795.

161. James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. March 2009;29(3):326-331.

162. Miller MA, Chalhoub M, Bourjeily G. Peripartum pulmonary embolism. Clin Chest Med. March 2011;32(1):147-164, ix-x.

163. Leung AN, Bull TM, Jaeschke R, et al. An official American Thoracic Society/Society of Thoracic Radiology clinical

practice guideline: evaluation of suspected pulmonary embo-lism in pregnancy. Am J Respir Crit Care Med. November 15, 2011;184(10):1200-1208.

164. Gammill HS, Jeyabalan A. Acute renal failure in pregnancy. Crit Care Med. October 2005;33(suppl 10):S372-S384.

165. Pan C, Perumalswami PV. Pregnancy-related liver diseases. Clin Liver Dis. February 2011;15(1):199-208.

166. Lee NM, Brady CW. Liver disease in pregnancy. World J Gastroenterol. February 28, 2009;15(8):897-906.

167. Brent R. The pulmonologist’s role in caring for pregnant women with regard to the reproductive risks of diagnostic radiological studies or radiation therapy. Clin Chest Med. March 2011;32(1):33-42, vii-viii.

168. Miller FC, Petrie RH, Arce JJ, Paul RH, Hon EH. Hyperventi-lation during labor. Am J Obstet Gynecol. October 15, 1974; 120(4):489-495.

169. Ralston DH, Shnider SM, DeLorimier AA. Uterine blood flow and fetal acid-base changes after bicarbonate administration to the pregnant ewe. Anesthesiology. April 1974;40(4):348-353.

170. Albright GA, Joyce TH, et al. Anesthesia in Obstetrics: Maternal, Fetal, and Neonatal Aspects. Boston, MA: Butterworth; 1986.

171. Brown RO, Vehe KL, Kaufman PA, Rogers R, Kudsk KA, Luther RW. Long-term enteral nutrition support in a preg-nant patient following head trauma. Nutr Clin Pract. June 1989;4(3):101-104.

Section11-O-Ref.indd 5 12/10/2014 8:08:29 PM

Chapter 128

REFERENCES

1. Lieberman P, Kemp S, Oppenheimer J, et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115:S483-S523.

2. Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Middleton E, Yunginger A, Reed BS, Adkinson NF, Busse WW, eds. Allergy: Principles and Practice. Vol II. Section E. 5th ed. St Louis, MO: Mosby-Yeark Book, Inc; 1998:1079-1092.

3. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. May 2004;113(5):832-836.

4. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol. March 2005;115(3):584-591.

5. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network sym-posium. J Allergy Clin Immunol. February 2006;117(2):391-397.

6. Simons FE, Sampson HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol. December 2008;122(6):1166-1168.

7. Clark S, Gaeta TJ, Kamarthi GS, Camargo CA. ICD-9-CM cod-ing of emergency department visits for food and insect sting allergy. Ann Epidemiol. September 2006;16(9):696-700.

8. Gaeta TJ, Clark S, Pelletier AJ, Camargo CA. National study of US emergency department visits for acute allergic reac-tions, 1993 to 2004. Ann Allergy Asthma Immunol. April 2007;98(4):360-365.

9. Lieberman P, Camargo CA Jr, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. November 2006;97(5):596-602.

10. Lieberman P. Anaphylaxis. In: Adkinson NF, Busse W, Bochner BS, et al., eds. Middleton’s Allergy: Principles and Practice. St Louis, MO: Mosby; 2008:1571-1576.

11. Sheikh A, Alves B. Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data. Clin Exp Allergy. October 2001;31(10):1571-1576.

12. Camargo CA Jr, Clark S, Kaplan MS, Lieberman P, Wood RA. Regional differences in EpiPen prescriptions in the United

States: the potential role of vitamin D. J Allergy Clin Immunol. July 2007;120(1):131-136.

13. Simons FE, Peterson S, Black CD. Epinephrine dispensing for the out-of-hospital treatment of anaphylaxis in infants and chil-dren: a population-based study. Ann Allergy Asthma Immunol. June 2001;86(6):622-626.

14. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol. July 2006;97(1):39-43.

15. Hamann CP. Natural rubber latex protein sensitivity. Rev Am J Contact Dermatitis. 1993;4:4-21.

16. Lieberman P. Anaphylaxis. In: Addkinson NF, Busse WW, Bochner DS, et al., eds. Middleton’s Allergy: Principles and Practice. St Louis, MO: Mosby, Inc; 2009:1027-1049.

17. Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol. February 2006;117(2 suppl mini-primer): S470-S475.

18. Derby CJ, Gowland MH, Hourihane JO. Sesame allergy in Britain: a questionnaire survey of members of the Anaphylaxis Campaign. Pediatr Allergy Immunol. March 2005;16(2):171-175.

19. Gangur V, Kelly C, Navuluri L. Sesame allergy: a growing food allergy of global proportions? Ann Allergy Asthma Immunol. July 2005;95(1):4-11; quiz 11-13, 44.

20. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagno-sis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. September 2010;126(3):477-480. e471-e442.

21. Moneret-Vautrin DA, Kanny G, Parisot L. First survey from the “Allergy Vigilance Network”: life-threatening food allergies in France. Allerg Immunol (Paris). June 2002;34(6):194-198.

22. Mertes PM, Laxenaire MC, Lienhart A, et al. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical prac-tice. J Investig Allergol Clin Immunol. 2005;15(2):91-101.

23. Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol. August 2004;93(2):137-141.

24. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. December 2007;120(6):1378-1381.

25. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. March 13, 2008;358(11):1109-1117.

Section11-O-Ref.indd 1 12/10/2014 8:08:29 PM

References2

26. Bush WH. Treatment of systemic reactions to contrast media. Urology. February 1990;35(2):145-150.

27. Shehadi WH, Toniolo G. Adverse reactions to contrast media: a report from the Committee on Safety of Contrast Media of the International Society of Radiology. Radiology. November 1980;137(2):299-302.

28. Bettmann MA. Ionic versus nonionic contrast agents for intravenous use: are all the answers in? Radiology. June 1990;175(3):616-618.

29. Golden DB. Insect sting allergy and venom immunother-apy: a model and a mystery. J Allergy Clin Immunol. March 2005;115(3):439-447; quiz 448.

30. Golden DB, Marsh DG, Kagey-Sobotka A, et al. Epidemiology of insect venom sensitivity. JAMA. July 14 1989;262(2):240-244.

31. Barnard JH. Studies of 400 Hymenoptera sting deaths in the United States. J Allergy Clin Immunol. November 1973;52(5):259-264.

32. Hepner DL, Castells MC. Latex allergy: an update. Anesth Analg. April 2003;96(4):1219-1229.

33. Aihara Y, Takahashi Y, Kotoyori T, et al. Frequency of food-dependent, exercise-induced anaphylaxis in Japanese junior-high-school students. J Allergy Clin Immunol. December 2001;108(6):1035-1039.

34. Sheffer AL, Soter NA, McFadden ER Jr, Austen KF. Exercise-induced anaphylaxis: a distinct form of physical allergy. J Allergy Clin Immunol. March 1983;71(3):311-316.

35. Dohi M, Suko M, Sugiyama H, et al. Food-dependent, exercise-induced anaphylaxis: a study on 11 Japanese cases. J Allergy Clin Immunol. January 1991;87(1, pt 1):34-40.

36. Shadick NA, Liang MH, Partridge AJ, et al. The natural history of exercise-induced anaphylaxis: survey results from a 10-year follow-up study. J Allergy Clin Immunol. July 1999;104(1):123-127.

37. Harada S, Horikawa T, Ashida M, Kamo T, Nishioka E, Ichihashi M. Aspirin enhances the induction of type I allergic symptoms when combined with food and exercise in patients with food-dependent exercise-induced anaphylaxis. Br J Dermatol. August 2001;145(2):336-339.

38. Wade JP, Liang MH, Sheffer AL. Exercise-induced anaphy-laxis: epidemiologic observations. Prog Clin Biol Res. 1989;297: 175-182.

39. Laroche D, Lefrancois C, Gerard JL, et al. Early diagnosis of anaphylactic reactions to neuromuscular blocking drugs. Br J Anaesth. December 1992;69(6):611-614.

40. Malinovsky JM, Decagny S, Wessel F, Guilloux L, Mertes PM. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiol Scand. February 2008;52(2):175-181.

41. Baldo BA, Fisher MM. Anaphylaxis to muscle relaxant drugs: cross-reactivity and molecular basis of binding of IgE antibod-ies detected by radioimmunoassay. Mol Immunol. December 1983;20(12):1393-1400.

42. Baldo BA, Fisher MM. Mechanisms in IgE-dependent anaphylaxis to anesthetic drugs. Ann Fr Anesth Reanim. 1993;12(2):131-140.

43. Baldo BA, Fisher MM. Substituted ammonium ions as aller-genic determinants in drug allergy. Nature. November 17-23, 1983;306(5940):262-264.

44. Leynadier F, Sansarricq M, Didier JM, Dry J. Prick tests in the diagnosis of anaphylaxis to general anaesthetics. Br J Anaesth. June 1987;59(6):683-689.

45. Fisher MM, Baldo BA. Immunoassays in the diagnosis of ana-phylaxis to neuromuscular blocking drugs: the value of mor-phine for the detection of IgE antibodies in allergic subjects. Anaesth Intensive Care. April 2000;28(2):167-170.

46. Birnbaum J, Porri F, Pradal M, Charpin D, Vervloet D. Allergy dur-ing anaesthesia. Clin Exp Allergy. October 1994;24(10):915-921.

47. Moscicki RA, Sockin SM, Corsello BF, Ostro MG, Bloch KJ. Anaphylaxis during induction of general anesthesia: subsequent evaluation and management. J Allergy Clin Immunol. September 1990;86(3, pt 1):325-332.

48. Rose M, Fisher M. Rocuronium: high risk for anaphylaxis? Br J Anaesth. May 2001;86(5):678-682.

49. Porri F, Lemiere C, Birnbaum J, et al. Prevalence of muscle relaxant sensitivity in a general population: implications for a preoperative screening. Clin Exp Allergy. January 1999;29(1): 72-75.

50. Levy J. Common anaphylactic and anaphylactoid reactions. In: Levy JH, ed. Anaphylactic Reactions in Anesthesia and Intensive Care. Boston, MA: Butterworth-Heinemann; 1993: p58.

51. Cook FV, Farrar WE Jr. Vancomycin revisited. Ann Intern Med. June 1978;88(6):813-818.

52. Park M, Markus P, Matesic D, Li JT. Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol. November 2006;97(5):681-687.

53. Newfield P, Roizen MF. Hazards of rapid administration of van-comycin. Ann Intern Med. October 1979;91(4):581.

54. Ring J. Anaphylactoid reactions to plasma substitutes. Int Anesthesiol Clin. Fall 1985;23(3):67-95.

55. Hirshman CA, Edelstein RA, Ebertz JM, Hanifin JM. Thiobarbiturate-induced histamine release in human skin mast cells. Anesthesiology. October 1985;63(4):353-356.

56. Dolovich J, Evans S, Rosenbloom D, Goodacre R, Rafajac FO. Anaphylaxis due to thiopental sodium anesthesia. Can Med Assoc J. August 23, 1980;123(4):292-294.

57. Harle DG, Baldo BA, Smal MA, Wajon P, Fisher MM. Detection of thiopentone-reactive IgE antibodies following anaphylac-toid reactions during anaesthesia. Clin Allergy. September 1986;16(5):493-498.

58. Gueant JL, Aimone-Gastin I, Namour F, Laroche D, Bellou A, Laxenaire MC. Diagnosis and pathogenesis of the anaphylactic and anaphylactoid reactions to anaesthetics. Clin Exp Allergy. September 1998;28(suppl 4):65-70.

59. Couldwell WT, Giannotta SL, Zelman V, DeGiorgio CM. Life-threatening reactions to propofol. Neurosurgery. December 1993;33(6):1116-1117.

60. Laxenaire MC, Gueant JL, Bermejo E, Mouton C, Navez MT. Anaphylactic shock due to propofol. Lancet. September 24, 1988;2(8613):739-740.

61. Fahmy NR. Hemodynamics, plasma histamine, and catechol-amine concentrations during an anaphylactoid reaction to morphine. Anesthesiology. September 1981;55(3):329-331.

62. Cromwell TA, Zsigmond EK. Hypersensitivity to intravenous morphine sulfate. Plast Reconstr Surg. August 1974;54(2): 224-227.

63. Rosow CE, Moss J, Philbin DM, Savarese JJ. Histamine release during morphine and fentanyl anesthesia. Anesthesiology. February 1982;56(2):93-96.

Section11-O-Ref.indd 2 12/10/2014 8:08:29 PM

References 3

64. Adourian U, Shampaine EL, Hirshman CA, Fuchs E, Adkinson NF Jr. High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men. Anesthesiology. February 1993;78(2):368-372.

65. Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol. January 1994;93(1, pt 1):117-125.

66. Horrow JC, Pharo GH, Levit LS, Freeland C. Neither skin tests nor serum enzyme-linked immunosorbent assay tests pro-vide specificity for protamine allergy. Anesth Analg. February 1996;82(2):386-389.

67. Kimmel SE, Sekeres MA, Berlin JA, Ellison N, DiSesa VJ, Strom BL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. J Am Coll Cardiol. December 1998;32(7):1916-1922.

68. Kindler CH, Bircher AJ. Anaphylactoid reactions to protamine. Anesthesiology. November 1996;85(5):1209-1210.

69. Alenius H, Kurup V, Kelly K, Palosuo T, Turjanmaa K, Fink J. Latex allergy: frequent occurrence of IgE antibodies to a cluster of 11 latex proteins in patients with spina bifida and histories of anaphylaxis. J Lab Clin Med. May 1994;123(5):712-720.

70. Granady L, Slater JE. History and diagnosis of latex allergy. Immunol Allergy Clin North Am. 1995:21-30.

71. Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. August 2008;8(4):310-315.

72. Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol. October 2009;124(4):639-646; quiz 647-648.

73. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. November 2008;9(11):1215-1223.

74. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. September 2007;120(3):506-515; quiz 516-517.

75. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. June 2003;98(6):1315-1324.

76. Zanoni G, Puccetti A, Dolcino M, et al. Dextran-specific IgG response in hypersensitivity reactions to measles-mumps-rubella vaccine. J Allergy Clin Immunol. December 2008;122(6):1233-1235.

77. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. June 5, 2008;358(23): 2457-2467.

78. Schwartz LB. Heparin comes clean. N Engl J Med. June 5, 2008;358(23):2505-2509.

79. Khodoun M, Strait R, Orekov T, et al. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. February 2009;123(2):342-351.

80. Simons FE. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol. October 2009;124(4):625-636; quiz 637-628.

81. Celik W, Pichler WJ, Adkinson NFJ. Drug allergy. In: Adkinson NJ, Bochner B, Busse W, Holgate S, Lemanske RJ, Simons F, eds. Middleton’s Allergy: Principles and Practice. 7th ed. St Louis, MO: Mosby, Inc; 2009:1205-1226.

82. Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media: a European multicenter study. Allergy. February 2009;64(2): 234-241.

83. Baba Y, Nishida K, Fujii Y, Hirano T, Hikida M, Kurosaki T. Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. Nat Immunol. January 2008;9(1):81-88.

84. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in ana-phylaxis: current and future approaches. J Allergy Clin Immunol. July 2007;120(1 suppl):S2-S24.

85. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. August 2006;26(3):451-463.

86. Komarow HD, Hu Z, Brittain E, Uzzaman A, Gaskins D, Metcalfe DD. Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol. October 2009;124(4):845-848.

87. Ono E, Taniguchi M, Mita H, et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy. January 2009;39(1):72-80.

88. Pushparaj PN, Tay HK, H’Ng SC, et al. The cytokine interleu-kin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A. June 16, 2009;106(24):9773-9778.

89. Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG. Elevated serum cytokines during human anaphylaxis: identifi-cation of potential mediators of acute allergic reactions. J Allergy Clin Immunol. October 2009;124(4):786-792. e784.

90. Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. January 3, 2008;358(1):28-35.

91. Olivera A, Mizugishi K, Tikhonova A, et al. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity. March 2007;26(3):287-297.

92. Chrusch C, Sharma S, Unruh H, et al. Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis. Am J Respir Crit Care Med. October 1999;160(4):1142-1149.

93. Mitsuhata H, Shimizu R, Yokoyama MM. Role of nitric oxide in anaphylactic shock. J Clin Immunol. November 1995;15(6): 277-283.

94. Rolla G, Nebiolo F, Guida G, Heffler E, Bommarito L, Bergia R. Level of exhaled nitric oxide during human anaphylaxis. Ann Allergy Asthma Immunol. August 2006;97(2):264-265.

95. Gupta A, Lin RY, Pesola GR, et al. Nitric oxide levels in patients with acute allergic reactions. Internet J Asthma Allergy Immunol. 2004;3(1):1-6.

96. Fisher M. Clinical observations on the pathophysiology and implications for treatment. In: Vincent JL, ed. Update in Intensive Care and Emergency Medicine. New York: Springer-Verlag; 1989:309-316.

97. Fisher MM. Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anaesth Intensive Care. February 1986;14(1):17-21.

98. Moss J, Fahmy NR, Sunder N, Beaven MA. Hormonal and hemodynamic profile of an anaphylactic reaction in man. Circulation. January 1981;63(1):210-213.

99. Rittweger R, Hermann K, Ring J. Increased urinary excretion of angiotensin during anaphylactoid reactions. Int Arch Allergy Immunol. July 1994;104(3):255-261.

Section11-O-Ref.indd 3 12/10/2014 8:08:29 PM

References4

100. Gawlik R, Rogala E, Jawor B. Endothelin-1 in plasma of patients with hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 1998;101:S160.

101. Silverman HJ, Van Hook C, Haponik EF. Hemodynamic changes in human anaphylaxis. Am J Med. August 1984;77(2):341-344.

102. Carlson RW, Schaeffer RC Jr, Puri VK, Brennan AP, Weil MH. Hypovolemia and permeability pulmonary edema associated with anaphylaxis. Crit Care Med. December 1981;9(12):883-885.

103. Sampson HA. Utility of food-specific IgE concentrations in pre-dicting symptomatic food allergy. J Allergy Clin Immunol. May 2001;107(5):891-896.

104. Braganza SC, Acworth JP, McKinnon DR, Peake JE, Brown AF. Paediatric emergency department anaphylaxis: different pat-terns from adults. Arch Dis Child. February 2006;91(2):159-163.

105. Viner NA, Rhamy RK. Anaphylaxis manifested by hypotension alone. J Urol. January 1975;113(1):108-110.

106. Valabhji J, Robinson S, Johnston D, Bellamy M, Davies W, Bain BJ. Unexplained loss of consciousness: systemic mastocytosis. J R Soc Med. March 2000;93(3):141-142.

107. Soreide E, Buxrud T, Harboe S. Severe anaphylactic reac-tions outside hospital: etiology, symptoms and treatment. Acta Anaesthesiol Scand. May 1988;32(4):339-342.

108. Brown SG, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intrave-nous adrenaline and volume resuscitation. Emerg Med J. March 2004;21(2):149-154.

109. Vivas D, Rubira JC, Ortiz AF, Macaya C. Coronary spasm and hypersensitivity to amoxicillin: Kounis or not Kounis syn-drome? Int J Cardiol. August 18, 2008;128(2):279-281.

110. Pfister CW, Plice SG. Acute myocardial infarction during a prolonged allergic reaction to penicillin. Am Heart J. December 1950;40(6):945-947.

111. Kounis NG, Grapsas ND, Goudevenos JA. Unstable angina, allergic angina, and allergic myocardial infarction. Circulation. December 21, 1999;100(25):e156.

112. Kounis NG, Zavras GM. Allergic angina and allergic myocardial infarction. Circulation. October 1, 1996;94(7):1789.

113. Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol. June 7, 2006;110(1):7-14.

114. Kounis GN, Soufras GD, Kouni SA, Kounis NG. Hypersensitivity myocarditis and hypersensitivity coronary syndrome (Kounis syndrome). Am J Emerg Med. May 2009;27(4):506-508; author reply 508.

115. Tavil Y, Turfan M, Turkoglu S, Abaci A. Kounis syndrome secondary to amoxicillin/clavulanic acid use. Int J Cardiol. February 20, 2008;124(1):e4-e7.

116. Biteker M, Duran NE, Biteker FS, et al. Allergic myocardial infarction in childhood: Kounis syndrome. Eur J Pediatr. January 2010;169(1):27-29.

117. Kogias JS, Sideris SK, Anifadis SK. Kounis syndrome associ-ated with hypersensitivity to hymenoptera stings. Int J Cardiol. January 8, 2007;114(2):252-255.

118. De Souza RL, Short T, Warman GR, Maclennan N, Young Y. Anaphylaxis with associated fibrinolysis, reversed with tranexamic acid and demonstrated by thrombelastography. Anaesth Intensive Care. August 2004;32(4):580-587.

119. Caughey GH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol. June 2006;117(6):1411-1414.

120. Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. Anesthesiology. December 1991;75(6):945-949.

121. Randall B, Butts J, Halsey JF. Elevated postmortem tryptase in the absence of anaphylaxis. J Forensic Sci. March 1995;40(2): 208-211.

122. Edston E, Gidlund E, Wickman M, Ribbing H, Van Hage-Hamsten M. Increased mast cell tryptase in sudden infant death - anaphylaxis, hypoxia or artefact? Clin Exp Allergy. December 1999;29(12):1648-1654.

123. Edston E, van Hage-Hamsten M. Mast cell tryptase and hemo-lysis after trauma. Forensic Sci Int. January 9, 2003;131(1):8-13.

124. Lin RY, Schwartz LB, Curry A, et al. Histamine and trypt-ase levels in patients with acute allergic reactions: an emer-gency department-based study. J Allergy Clin Immunol. July 2000;106(1, pt 1):65-71.

125. Ebo DG, Hagendorens MM, Bridts CH, Schuerwegh AJ, De Clerck LS, Stevens WJ. In vitro allergy diagnosis: should we fol-low the flow? Clin Exp Allergy. March 2004;34(3):332-339.

126. Eberlein-Konig B, Schmidt-Leidescher C, Rakoski J, Behrendt H, Ring J. In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy. J Investig Allergol Clin Immunol. 2006;16(1):5-10.

127. Zhou X, Buckley MG, Lau LC, Summers C, Pumphrey RSH, Walls AF. Mast cell carboxypeptidase as a new clinical marker for anaphylaxis. J Allergy Clin Immunol. 2006;117:S85.

128. Simons E. Anaphylaxis. J Allergy Clin Immunol. 2010;125: s161-s181.

129. Simons FE. Anaphylaxis, killer allergy: long-term manage-ment in the community. J Allergy Clin Immunol. February 2006;117(2):367-377.

130. Pereira B, Venter C, Grundy J, Clayton CB, Arshad SH, Dean T. Prevalence of sensitization to food allergens, reported adverse reaction to foods, food avoidance, and food hyper-sensitivity among teenagers. J Allergy Clin Immunol. October 2005;116(4):884-892.

131. Sampson HA, Burks AW. Adverse reactions to foods. In: Adkinson NFJ, Bochner BS, Busse WW, Holgate ST, Lemanske RFJ, Simons FER, eds. Middleton’s Allergy: Principles and Practice. 7th ed. St Louis, MO: Mosby; 2009:1139-1167.

132. Mertes PM, Laxenaire MC. Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol. April 2002;19(4):240-262.

133. Hamilton RG, Adkinson NF Jr. 23. Clinical laboratory assess-ment of IgE-dependent hypersensitivity. J Allergy Clin Immunol. February 2003;111(2 suppl):S687-S701.

134. Yunginger JW. Natural rubber latex allergy. In: Adkinson NFJ, Bochner BS, Busse WW, Holgate ST, Lemanske RFJ, Simons FER, eds. Middleton’s Allergy: Principles and Practice. Vol 2. 7th ed. St Louis, MO: Mosby, Inc; 2009:1019-1026.

135. Gueant JL, Mata E, Monin B, et al. Evaluation of a new reactive solid phase for radioimmunoassay of serum specific IgE against muscle relaxant drugs. Allergy. August 1991;46(6):452-458.

136. Guilloux L, Ricard-Blum S, Ville G, Motin J. A new radioim-munoassay using a commercially available solid support for the detection of IgE antibodies against muscle relaxants. J Allergy Clin Immunol. August 1992;90(2):153-159.

137. Sturm GJ, Kranzelbinder B, Sturm EM, Heinemann A, Groselj-Strele A, Aberer W. The basophil activation test in the

Section11-O-Ref.indd 4 12/10/2014 8:08:30 PM

References 5

diagnosis of allergy: technical issues and critical factors. Allergy. September 2009;64(9):1319-1326.

138. Steckelbroeck S, Ballmer-Weber BK, Vieths S. Potential, pit-falls, and prospects of food allergy diagnostics with recombi-nant allergens or synthetic sequential epitopes. J Allergy Clin Immunol. June 2008;121(6):1323-1330.

139. Lin J, Bardina L, Shreffler WG, et al. Development of a novel peptide microarray for large-scale epitope mapping of food allergens. J Allergy Clin Immunol. August 2009;124(2): 315-322.

140. Cerecedo I, Zamora J, Shreffler WG, et al. Mapping of the IgE and IgG4 sequential epitopes of milk allergens with a pep-tide microarray-based immunoassay. J Allergy Clin Immunol. September 2008;122(3):589-594.

141. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. August 2008;63(8):1061-1070.

142. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy. February 2009;64(2):204-212.

143. Guidelines to minimize the risk from systemic reactions caused by immunotherapy with allergenic extracts. AAAI Board of Directors. American Academy of Allergy and Immunology. J Allergy Clin Immunol. April 1994;93(4):811-812.

144. Bousquet J, Lockey R, Malling HJ, et al. Allergen immu-notherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. November 1998;81(5, pt 1):401-405.

145. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. December 2007;120(6):1373-1377.

146. Committee on Drugs: anaphylaxis. Pediatrics. January 1973; 51(1):136-140.

147. The use of epinephrine in the treatment of anaphylaxis. AAAI Board of Directors. J Allergy Clin Immunol. October 1994; 94(4):666-668.

148. Winslow CM, Austen KF. Enzymatic regulation of mast cell activation and secretion by adenylate cyclase and cyclic AMP-dependent protein kinases. Fed Proc. January 1982; 41(1):22-29.

149. Fisher MM. The management of anaphylaxis. Med J Aust. May 21, 1977;1(21):793.

150. Fisher M. Blood volume replacement in acute anaphylactic cardiovascular collapse related to anaesthesia. Br J Anaesth. October 1977;49(10):1023-1026.

151. Beaupre PN, Roizen MF, Cahalan MK, Alpert RA, Cassorla L, Schiller NB. Hemodynamic and two-dimensional transesopha-geal echocardiographic analysis of an anaphylactic reaction in a human. Anesthesiology. May 1984;60(5):482-484.

152. Philbin DM, Moss J, Akins CW, et al. The use of H1 and H2 his-tamine antagonists with morphine anesthesia: a double-blind study. Anesthesiology. September 1981;55(3):292-296.

153. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. November 2000;36(5):462-468.

154. De Soto H, Turk P. Cimetidine in anaphylactic shock refractory to standard therapy. Anesth Analg. August 1989;69(2):264-265.

155. Yarbrough JA, Moffitt JE, Brown DA, Stafford CT. Cimetidine in the treatment of refractory anaphylaxis. Ann Allergy. September 1989;63(3):235-238.

156. Mayumi H, Kimura S, Asano M, Shimokawa T, Au-Yong TF, Yayama T. Intravenous cimetidine as an effective treatment for systemic anaphylaxis and acute allergic skin reactions. Ann Allergy. June 1987;58(6):447-450.

157. Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell SC. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med. March 1992;21(3):237-242.

158. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. August 2007;62(8):830-837.

159. Gueugniaud PY, David JS, Chanzy E, et al. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resusci-tation. N Engl J Med. July 3, 2008;359(1):21-30.

160. Choong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. Am J Respir Crit Care Med. October 1, 2009;180(7):632-639.

161. De Backer D, Biston P, Devriendt J, et al. Comparison of dopa-mine and norepinephrine in the treatment of shock. N Engl J Med. March 4, 2010;362(9):779-789.

162. Kill C, Wranze E, Wulf H. Successful treatment of severe ana-phylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol. July 2004;134(3):260-261.

163. Williams SR, Denault AY, Pellerin M, Martineau R. Vasopressin for treatment of shock following aprotinin administration. Can J Anaesth. February 2004;51(2):169-172.

164. Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy. October 2010;65(10):1205-1211.

165. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. September 2005;95(3):217-226; quiz 226, 258.

166. Vander Zanden JA, Valuck RJ, Bunch CL, Perlman JI, Anderson C, Wortman GI. Systemic adverse effects of ophthalmic beta-blockers. Ann Pharmacother. December 2001;35(12):1633-1637.

167. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Goodman LS, Limbird LE, Milinoff PB, Ruddon RW, Gilman AG, eds. The Pharmacologic Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1990:209.

168. Hiatt WR, Wolfel EE, Stoll S, et al. Beta-2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. Clin Pharmacol Ther. January 1985;37(1):2-6.

169. Motulsky HJ, Insel PA. Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations. N Engl J Med. July 1, 1982;307(1):18-29.

170. Zaloga GP, DeLacey W, Holmboe E, Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann Intern Med. July 1986;105(1):65-66.

171. Pollack CV Jr. Utility of glucagon in the emergency department. J Emerg Med. March-April 1993;11(2):195-205.

172. Sherman MS, Lazar EJ, Eichacker P. A bronchodilator action of glucagon. J Allergy Clin Immunol. May 1988;81(5, pt 1):908-911.

173. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J. April 2005;22(4):272-273.

Section11-O-Ref.indd 5 12/10/2014 8:08:30 PM

References6

174. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. August 15, 1991;115(4):270-276.

175. SF K. Current concepts in pathophysiology, diagnosis, and management of anaphylaxis. Immunol Allergy Clin North Am. 2001;21:611-634.

176. Evora PR, Simon MR. Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphy-lactic hypotension with methylene blue. Ann Allergy Asthma Immunol. October 2007;99(4):306-313.

177. Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD. Epidemiology of anaphylaxis in Olmsted County: a population-based study. J Allergy Clin Immunol. August 1999;104(2, pt 1):452-456.

178. Simons FE, Peterson S, Black CD. Epinephrine dispensing patterns for an out-of-hospital population: a novel approach to studying the epidemiology of anaphylaxis. J Allergy Clin Immunol. October 2002;110(4):647-651.

179. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS. Epidemiology of anaphylaxis among children

and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol. March 2004;113(3):536-542.

180. Helbling A, Hurni T, Mueller UR, Pichler WJ. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy. February 2004;34(2):285-290.

181. Poulos LM, Waters AM, Correll PK, Loblay RH, Marks GB. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol. October 2007;120(4):878-884.

182. Decker WW, Campbell RL, Manivannan V, et al. The etiol-ogy and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol. December 2008;122(6):1161-1165.

183. Lin RY, Anderson AS, Shah SN, Nurruzzaman F. Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990-2006. Ann Allergy Asthma Immunol. October 2008;101(4):387-393.

184. Sheikh A, Hippisley-Cox J, Newton J, Fenty J. Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England. J R Soc Med. March 2008;101(3):139-143.

Section11-O-Ref.indd 6 12/10/2014 8:08:30 PM

Chapter 129

REFERENCES

1. World Health Organization. International Drug Monitoring: The Role of the Hospital. Technical Report Series. Geneva: World Health Organization; 1966.

2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200.

3. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general units. Crit Care Med. 1997;25:1289.

4. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reac-tions: a report from the Boston Collaborative Drug Surveillance Program on 15438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358.

5. Rawlins M, Thompson J. Mechanisms of adverse drug reac-tions. In: Davies D, ed. Textbook of Adverse Drug Reactions. 4th ed. Oxford, England: Oxford University Press; 1991:224.

6. Hurwitz N. Admissions to hospital due to drugs. Br Med J. 1969;1(643):539.

7. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137:765.

8. Gell PGH, Coombs RRA. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Hachmann PJ, eds. Clinical Aspects of Immunology. Oxford, England: Blackwell Scientific Publications; 1975;761.

9. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001;161:15-21.

10. Katta R, Anusuri V. Serum sickness-like reaction to cefurox-ime: a case report and review of literature. J Drugs Dermatol. 2007;6(7):747-748.

11. Berman B, Villa AM. Is eosinophilia helpful in diagnosing drug eruptions? SkinMED. 2002;1:147.

12. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987;316:1622.

13. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367.

14. Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol. 1994;5:769.

15. Duvic M, Lemak NA, Valero V, et al. A randomized trial of min-oxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74.

16. Davis M, DeSantis D, Klemm K. A flow sheet for follow-up after chemotherapy extravasation. Oncol Nurs Forum. 1995; 22:979.

17. Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfox-ide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995;13:2851.

18. Baack BR, Burgdorf WH. Chemotherapy-induced acral ery-thema. J Am Acad Dermatol. 1991;24:457.

19. Vukelja S, Baker W, Burris H, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with Taxotere. J Natl Cancer Inst. 1993;85:1432.

20. Hwang SW, Hong SK, Kim SH, Seo JK, Lee D, Sung HS. A Hydroxyurea-induced leg ulcer. Ann Dermatol. 2009;21(1):39-41.

21. Ben-Amitai D, Hodak E, David M. Cutaneous ulceration: an unusual sign of methotrexate toxicity. First report in a patient without psoriasis. Ann Pharmacother. 1998;32(6)651-653.

22. Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in preven-tion of recurrent neutrophilic eccrine hidradenitis. J AM Acad Dermatol. 2006;35:819-822.

23. Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitiv-ity and cross-reactivity to heparins and danaparoid: a prospec-tive study. Dermatol Surg. 2001;27:47.

24. Harenberg J, Hoffmann U, Huhle G, et al. Cutaneous reactions to anticoagulants: recognition and management. Am J Clin Dermatol. 2001;2:69.

25. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92:494.

26. Harenberg J, Huhle G, Wang L, et al. Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Allergy. 1999;54:473.

27. Gelwix TJ, Beeson MS. Warfarin-induced skin necrosis. Am J Emerg Med. 1998;16:541.

28. Faraci PA, Deterling RA Jr, Stein AM, et al. Warfarin-induced necrosis of the skin. Surg Gynecol Obstet. 1978;146:695.

29. Scarff CE, Baker C, Hill P, Foley P. Late-onset warfarin necrosis. Australas J Dermatol. 2002;43:202.

Section11-O-Ref.indd 1 12/10/2014 8:08:30 PM

References2

30. Barnes J. Quality, efficacy and safety of complementary medi-cines: fashions, facts and the future. Part II: efficacy and safety. Br J Clin Pharmacol. 2003;55:331.

31. Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998;104:170.

32. Meredith MJ. Herbal nutriceuticals: a primer for dentists and dental hygienists. J Contemp Dent Pract. 2001;2:1.

33. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med. 2002;30:1899.

34. Sirinek KR, Levine BA. High-dose vasopressin for acute variceal hemorrhage. Clinical advantages without adverse effects. Arch Surg. 1988;123:876.

35. Korenberg RJ, Landau-Price D, Penneys NS. Vasopressin-induced bullous disease and cutaneous necrosis. J Am Acad Dermatol. 1986;15(2, pt 2):393.

36. Kim EH, Lee SH, Byun SW, et al. Skin necrosis after a low-dose vasopressin infusion through a central venous catheter for treating septic shock. Korean J Intern Med. 2006;21(4):287-290.

37. Dünser MW, Mayr AJ, Tür A, et al. Ischemic skin lesions as a complication in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003;31:1394.

38. Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematous pustulosis: an overview of the clini-cal, immunological and diagnostic concepts. Eur J Dermatol. 20(4):425-433. Epub 2010 June 14.

39. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600.

40. Bachot N, Roujeau JC. Physiopathology and treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol. 2001;1:293.

41. Becker DS. Toxic epidermal necrolysis. Lancet. 1998;351:1417. 42. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epider-

mal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323.

43. Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J Burn Care Rehabil. 1997;18:417.

44. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272.

45. Ducic I, Shalom A, Rising W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg. 2002;110:768.

46. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest. 2000;115:149-153.

47. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35(5, pt 1):757.

48. Nagata S. Apoptosis by death factor. Cell. 1997;88:355. 49. Iwai K, Miyawaki T, Takizawa T, et al. Differential expression

of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood. 1994;84:1201.

50. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med. 1996;2:317.

51. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble fas ligand. Am J Pathol. 2003;162:1515.

52. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome), incidence and drug etiology in France, 1981–1985. Arch Dermatol. 1990;126:37.

53. Roupe G, Ahlmen M, Fagerberg B, et al. Toxic epidermal necrol-ysis with extensive mucosal erosions of the gastrointestinal and respiratory tracts. Int Arch Allergy Appl Immunol. 1986;80:145.

54. Frenia ML, Schauben P. Use of silver sulfadiazine in Stevens-Johnson syndrome. Ann Phramacother. 1994;28:736.

55. Heimbach DM, Engrav LH, Marvin JA, et al. Toxic epidermal necrolysis. A step forward in treatment. JAMA. 1987;257:2171.

56. Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333:1475.

57. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. Br J Dermatol. 1993;128:357.

58. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49:769.

59. Halebian PH, Madden MR, Finklestein JL, et al. Improved burn center survival of patients with toxic epidermal necrolysis man-aged without corticosteroids. Ann Surg. 1986;204:503.

60. Guibal F, Bastuji-Garin S, Chosidow O, et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol. 1995;131:669.

61. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epider-mal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490.

62. Stella M, Cassano P, Bollero D, et al. Toxic epidermal necroly-sis treated with intravenous high-dose immunoglobulins: our experience. Dermatology. 2001;203:45.

63. Prins C, Kerdel FA, Padilla RS, et al. for the TEN-IVIG Study Group. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analy-sis of 48 consecutive cases. Arch Dermatol. 2003;139:26.

64. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intra-venous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experi-ence. Arch Dermatol. 2003;139:39.

65. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex inter-play among herpesvirus and antiviral and antidrug immune responses. Allergol Int. 2006;55:1-8.

66. Gruchalla RS. Allergic disorders 10. Drug allergy. J Allergy Clin Immunol. 2003;111(suppl):S548.

67. Descamps V, Valance A, Edlinger C, et al. Association of her-pes virus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137:301.

68. Kurzock R, Cohen PR. Mucocutaneous paraneoplastic manifes-tations of hematologic malignancies. Am J Med. 1995;99:207.

69. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol. 1991;30:307.

70. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140:84.

Section11-O-Ref.indd 2 12/10/2014 8:08:30 PM

References 3

71. Snow JL, Gibson LE. The role of genetic variation in thiopu-rine methyltransferase activity and the efficacy and/or side effects of azathioprine in dermatologic patients. Arch Dermatol. 1995;131:193.

72. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intra-venous immunoglobulin. J Am Acad Dermatol. 2002;47:358.

73. Nousari HC, Griffin WA, Anhalt GJ. Successful treatment for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol. 1998;39,497.

74. Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med. 2000;18:288.

75. Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol. 2002;147:214.

76. Smith KE, Fenske KA. Cutaneous manifestations of alcohol abuse. J Am Acad Dermatol. 2000;43(1, pt 1):1.

77. Spencer JM, Silvers DN, Grossman ME. Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug erup-tion? Br J Dermatol. 1994;130:514.

78. Zelickson BD, Muller SA. Generalized pustular psoriasis: a review of 63 cases. Arch Dermatol. 1991;127:1339.

79. Roenigk HH Jr. Acitretin combination therapy. J Am Acad Dermatol. 1999;41:S18.

80. Karakayli G, Beckham G, Orengo I, Rosen T. Exfoliative derma-titis. Am Fam Phys. 1999;59:625.

81. Lotti T. The purpuras. Int J Dermatol. 1994;33:1. 82. Touart DM, Sau P. Cutaneous deposition diseases. Part 1. J Am

Acad Dermatol. 1998;39:149. 83. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol.

2003;48:311. 84. Piette WW. Hematologic diseases. In: Freedberg IM, Wolff K,

Austen KF, et al., eds. Dermatology in General Medicine. 5th ed. New York: McGraw-Hill; 1993:1867.

85. Horn TD. Graft-versus-host disease. In: Freedberg IM, Wolff K, Austen KF, et al., eds. Dermatology in General Medicine. 5th ed. New York: McGraw-Hill, 1993:1426.

86. Anasetti C. Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation. Transplantation. 2004;77:79.

87. Behar E, Chao NJ, Hiraki, et al. Polymorphism of adhesion mol-ecule CD31 and its role in acute graft-versus-host disease. New Engl J Med. 1996;334:286.

88. Vogelsang G, Hess A. Graft versus host disease: new directions for a persistent problem. Blood. 1994;84:2061.

89. Bhushan M, Chalmers RJ, Cox NH. Acute oedema blisters: a report of 13 cases. Br J Dermatol. 2001;144(3):580-582.

90. Seal DV. Necrotizing fasciitis. Curr Opin Infect Dis. 2001;14:127. 91. Nouraei SA, Hodgson EL, Malata CM. Cervicofacial. J Wound

Care. 2003;12:147. 92. Praba-Egge AD, Lanning D, Broderick TJ, Yelon JA. Necrotizing

fasciitis of the chest and abdominal wall arising from an empy-ema. J Trauma. 2004;56(6):1356-1361.

93. Chan ATY, Cleeve V, Daymond TJ. Necrotizing fasciitis in a patient receiving infliximab or rheumatoid arthritis. Postgrad Med. 2002;78:47.

94. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis. 1992;14:2.

95. Guiliano A, Lewis F Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg. 1977;134:52.

96. Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol. 1998;39:383.

97. Reingold AL, Hargrett NT, Shands KN, et al. Toxic shock syn-drome surveillance in the United States, 1980–1981. Ann Intern Med. 1982;96:875.

98. Case definitions for public health surveillance MMWR Morb Mortal Wkly Rep 1990; 39(RR-13):1. CDC: case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep. 1997;46(RR-10):39.

99. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA. 1993;269:390.

100. Musser JM, Hauser AR, Kim MH, et al. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A. 1991;88:2668.

101. Hackett SP, Stevens DL. Superantigens associated with staphy-lococcal and streptococcal toxic shock syndromes are potent inducers of tumor necrosis factor beta synthesis. J Infect Dis. 1993;168:232-235.

102. Wolf JE, Rabinowitz LG. Streptococcal toxic shock-like syn-drome. Arch Dermatol. 1995;131:73.

103. Kaul R, McGeer A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative obser-vational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999;28:800-807.

104. Norrby-Teglund A, Muller MP, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infec-tions using an aggressive medical regimen including intrave-nous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis. 2005;37:166-172.

105. Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. J Am Acad Dermatol. 1994;30:319.

106. Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. J Am Acad Dermatol. 1994;30:319.

107. Khuong MA, Chosidow O, El-Soln N, et al. Staphylococcal scalded skin syndrome in an adult: possible influence of non-steroidal anti-inflammatory drugs. Dermatologica. 1993;186:153.

108. Forkner CE, Frei E III, Edgcomb JH, Utz JP. Pseudomonas septicemia. Observations on twenty-three cases. Am J Med. 1958;25:877.

109. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145:1621.

110. Holland PC, Thompson D, Hancock S, Hodge D. Calciphylaxis, proteases, and purpura: an alternative hypothesis for the severe shock, rash, and hypocalcemia associated with meningococcal septicemia. Crit Care Med. 2002;30:2757.

111. Galimand, M, Gerbaud, G, Guibourdenche, M, et al. High-level chloramphenicol resistance in Neisseria meningitidis [pub-lished erratum appears in Engl J Med 1999 Mar 11;340(10):824]. N Engl J Med. 1998;339:868.

112. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone, An Imprint of Elsevier.

Section11-O-Ref.indd 3 12/10/2014 8:08:31 PM

References4

113. Cardullo AC, Silvers DN, Grossman ME. Janeway lesions and Osler’s nodes: a review of histopathologic findings. J Am Acad Dermatol. 1990;22:1088.

114. Yee J, McAllister CK. Osler’s nodes and the recognition of infec-tive endocarditis: a lesion of diagnostic importance. South Med J. 1987;80:753.

115. Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am. 2001;85:19.

116. Zirn JR, Tompkins SD, Huie C, Shea CR. Rapid detection and distinction of cutaneous herpesvirus infections by direct immu-nofluorescence. J Am Acad Dermatol. 1995;33:724.

117. Brown TJ, McCrary M, Tyring SK. Antiviral agents: non- antiviral drugs. J Am Acad Dermatol. 2002;47:581.

118. Diven DG. An overview of poxviruses. J Am Acad Dermatol. 2001;44:1.

119. Beachkofsky TM, Carrizales SC, Bidinger JJ, Hrncir DE, Whittemore DE, Hivnor CM. Adverse events following small-pox vaccination with ACAM2000 in a military population. Arch Dermatol. 2010;146(6):656-661.

120. Vora S et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis. 2008;46(10):1555-1561.

121. Garman ME, Tyring SK. The cutaneous manifestations of HIV infection. Dermatol Clin. 2002;20:193.

122. Geraminejad P, Memar O, Aronson I, et al. Kaposi’s sarcoma and other manifestations of human herpes virus 8. J Am Acad Dermatol. 2002;47:641.

123. Gates AE, Kaplan LD. Biology and management of AIDS-associated non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am. 2003;17:821.

124. Stephenson J. Can a common medical practice transform Candida infections from benign to deadly? JAMA. 2001;286:2531.

125. Roth JS, Grossman ME. Cutaneous lesions of disseminated can-didiasis. N Engl J Med. 1994;330:1650.

126. Ostrosky-Zeichner L, Rex JH, Bennet J, Kullberg B. Deeply invasive candidiasis. Infect Dis Clin North Am. 2002;16:821.

127. Gonzalez G, Rinaldi M, Sugar AM. Zygomycosis. Infect Dis Clin North Am. 2002;16:895.

128. Welsh O, Schimid-Grendelmeier P, Stingl P, et al. Tropical der-matology. Part II. J Am Acad Dermatol. 2002;46:748.

129. National Pressure Ulcer Advisory Panel. http://www.npuap.org. Accessed October 10, 2010.

130. Fife C, Otto G, Capsuto E, et al. Incidence of pressure ulcers in a neurologic intensive care unit. Crit Care Med. 2001;29:283.

131. Colwell JC, Foreman MD, Trotter JP. A comparison of the efficacy and cost effectiveness of two methods of managing pressure ulcers. Decubitus. 1993;6:28.

Section11-O-Ref.indd 4 12/10/2014 8:08:31 PM

Chapter 130

REFERENCES

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303(3): 235-241.

2. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010;303(3):242-249.

3. Mitka M. Economist takes aim at “big fat” US lifestyle. JAMA. 2003;289(1):33-34.

4. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physi-cal activities. Med Sci Sports Exerc. 1993;25(1):71-80.

5. Hu FB, Li TY, Colditz GA, et al. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA. 2003;289(14):1785-1791.

6. Robinson TN. Reducing children’s television viewing to prevent obesity: a randomized controlled trial. JAMA. 1999;282(16):1561-1567.

7. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci. 2008;1129:287-304.

8. Fonken LK, Workman JL, Walton JC, et al. Light at night increases body mass by shifting the time of food intake. Proc Natl Acad Sci USA. 2010;107(43):18664-18669.

9. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900,000 adults: prospective studies. Lancet. 2009;373(9669):1083-1096.

10. Poirier P, Giles TD, Bray GA. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898-918.

11. Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost. 2009;35:451-457.

12. Schunkert H. Obesity and target organ damage: the heart. Int J Obesity. 2002;26(suppl 4):S15-S20.

13. Lee R, McNicholas WT. Obstructive sleep apnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2011;17(2);79-83.

14. Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respiratory Care. 2010;55(10):1347-1365.

15. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease. Risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925-1932.

16. Koenig SM. Pulmonary complications of obesity. Am J Med Sci. 2001;321(4):249-279.

17. Unterborn J. Pulmonary function testing in obesity, pregnancy, and extremes of body habitus. Clin Chest Med. 2001;22(4):759-767.

18. Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. J Appl Physiol. 2010;108:206-211.

19. Sharp JT, Henry JP, Swaeny SK, et al. Effects of mass loading the respiratory system in man. J Appl Physiol. 1964;19:959-966.

20. Rubinstein I, Zamel N, DuBarry L, et al. Airflow limita-tion in morbidly obese, nonsmoking men. Ann Intern Med. 1990;112(11):828-832.

21. Douglas FG, Chong PY. Influence of obesity on peripheral air-ways patency. J Appl Physiol. 1972;33(5):559-563.

22. Kaw R, Hernandez AV, Walker E, et al. Determinants of hypercapnea in obese patients with obstructive sleep apnea: a systematic review of metaanalysis of cohort studies. Chest. 2009;136:787-796.

23. Squier SB, Patil SP, Schneider H, et al. Effect of end-expiratory lung volume on upper airway collapsibility in sleep men and women. J Appl Physiol. 2010;109:977-985.

24. Owens RL, Malhotra A, Eckert DJ, et al. The influence of end-expiratory lung volume on measurements of pharyngeal col-lapsibility. J Appl Physiol. 2010;108:445-451.

25. Somers VK, White DP, Amin R, et al. Sleep apnea and cardio-vascular disease. An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). J Am Coll Cardiol. 2008;52:686-717.

26. DeKeulenaer BL, DeWaele JJ, Powell B, et al. What is normal intraabdominal pressure and how is it affected by positioning, body mass and positive end-expiratory pressure? Intensive Care Med. 2009;35:969-976.

27. Malbrain ML, Chiumello D, Pelosi P, et al. Prevalence of intra-abdominal hypertension in critically ill patients: a multicenter epidemiological study. Intensive Care Med. 2004;30:822-829.

Section11-O-Ref.indd 1 12/10/2014 8:08:31 PM

References2

28. Behazin N, Jones SB, Cohen RI, et al. Respiratory restric-tion and elevated pleural and esophageal pressures in morbid obesity. J Appl Physiol. 2010;108:212-218.

29. Hunley TE, Ma L-J, Kon V. Scope and mechanisms of obesity- related renal disease. Curr Opin Nephrol Hypertens. 2010;19(3):227-234.

30. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. 2011;13:71-76.

31. Kress JP, Pohlman AS, Alverdy J, et al. The impact of morbid obesity on oxygen cost of breathing at rest. Am J Respir Crit Care Med. 1999;160(3):883-886.

32. Kaufman BJ, Ferguson MH, Cherniack RM. Hypoventilation in obesity. J Clin Invest. 1959;38(3):500-507.

33. Fein A, Grossman RF, Jones JG, et al. The value of edema fluid protein measurement in patients with pulmonary edema. Am J Med. 1979;67(1):32-38.

34. Ogunnaike BO, Jones SB, Jones DB, et al. Anesthetic consider-ations for bariatric surgery. Anesth Analg. 2002;95(6):1793-1805.

35. Kristensen MS. Airway management and morbid obesity. Eur J Anaesthesiol. 2010;27:923-927.

36. Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extuba-tion. N Engl J Med. 2004;350(24):2452-2460.

37. Vasu TS, Doghramji K, Cavallazzi R, et al. Obstructive sleep apnea syndrome and postoperative complications. Clinical Use of the STOP-BANG questionnaire. Arch Otolaryngol Head Neck Surg. 2010;136(10):1020-1024.

38. El Solh AA. Airway management in the obese patient. Clin Chest Med. 2009;30:555-568.

39. Port AM, Apovian C. Metabolic support of the obese intensive care unit patient: a current perspective. Curr Opin Clin Nutr Metab Care. 2010;13:184-191.

40. Dickerson RN, Drover JW. Monitoring nutrition therapy in the critically ill patient with obesity. JPEN. 2011;35:44S.

41. McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). JPEN. 2009;33:277-316.

42. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88(1):1-7.

43. Greenblatt DJ, Abernathy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27-35.

44. Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infu-sion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide: a clinical and pharmacokinetic study. Anesthesiology. 1993;78(4):657-665.

45. Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg. 2000;10(1):7-13.

46. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest. 2008;133(6) 381S-453S.

47. Winkelman C, Maloney B. The impact of obesity on critical care resource use and outcomes. Crit Care Nurs Clin N Am. 2009;21:403-422.

48. McAtee M, Personett RJ. Obesity-related risks and prevention strategies for critically ill adults. Crit Care Nurs Clin N Am. 2009;21:391-401.

49. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752.

50. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-761.

51. The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-454.

52. El-Solh A, Sikka P, Bozkanat E, et al. Morbid obesity in the medical ICU. Chest. 2001;120(6):1989-1997.

53. Hogue CW Jr, Stearns JD, Colantuoni E, et al. The impact of obesity on outcomes after critical illness: a meta-analysis. Intensive Care Med. 2009;35:1152-1170.

54. Akinnusi M, Pineda L, El Solh A. Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med. 2008;36:151-158.

Section11-O-Ref.indd 2 12/10/2014 8:08:31 PM

Chapter 131

REFERENCES

1. Koutsavlis AT, Kosatsky T. Environmental-temperature injury in a Canadian metropolis. J Environ Health. 2003;66:40.

2. Schneider SM, Danzl DF. Hypothermia: from recognition to re-warming. Emerg Med Rep. 1992;13:1.

3. Bangs CC. Hypothermia and frostbites. Emerg Med Clin North Am. 1984;2:475.

4. Granberg PO. Human physiology under cold exposure. Arctic Med Res. 1991;50(suppl 6):23.

5. Mcculough L, Arora S. Diagnosis and treatment of hypother-mia. American Family Physician. 2004;70:2325.

6. Danzl DF, Pozos RS, Hamlet MP. Accidental hypothermia. In: Auerbach PS, ed. Wilderness Medicine. St Louis, MO: Mosby; 1995: 51.

7. Danzl DF, Pozos RS. Accidental hypothermia. N Engl J Med. 1994;331:1756.

8. Jacobsen TD, Krenzelok EP, Shicker L, Weiner SL. Environ-mental emergencies. Disease-A-Month. 1997;43:809.

9. Lee-Chiong TL, Stitt JT. Disorders of temperature regulation. Compr Ther. 1995;21:697.

10. Danzl DF, Pozos RS, Auerbach PS, et al. Multicenter hypother-mia survey. Ann Emerg Med. 1987;16:1042.

11. Center for Disease Control. Hypothermia-related deaths—United States, 2003–2004. MMWR. 2005;54:173.

12. Center for Disease Control. Hypothermia-related deaths—Virginia, November 1996–April 1997. MMWR. 1997;46:1157.

13. Jolly T, Ghezzi KT. Accidental hypothermia. Emerg Med Clin North Am. 1992;10:311.

14. Weinberg AD. Hypothermia. Ann Emerg Med. 1993;22(pt 2):370. 15. Tsuei BJ, Kearney PA. Hypothermia in the trauma patient.

Injury, Int J Care Injured. 2004;35:7. 16. Wang HE, Callaway CE, Peitzman AB, Tisherman SA.

Admission hypothermia and outcome after major trauma. Crit Care Med. 2005;33:1296.

17. Bartley B, Crnkovich DJ, Usman AR, Carlson RW. How to rec-ognize hypothermia in critically ill patients. J Crit Care Illness. 1996;11:118.

18. Antretter H, Dapunt OE, Bonatti J. Management of profound hypothermia. Br J Hosp Med. 1995;54:215.

19. Silfvast T, Pettila V. Outcome from severe accidental hypo-thermia in Southern Finland—a 10-year review. Resuscitation. 2003;59:285.

20. Delaney KA, Howland MA, Vassallo S, Goldfrank LR. Assessment of acid-base disturbances in hypothermia and their physiologic consequences. Ann Emerg Med. 1989;18:72.

21. Larach MG. Accidental hypothermia. Lancet. 1995;345:493. 22. Patel A, Gestos JP, Moussa G, et al. The Osborn wave of hypo-

thermia in normothermic patients. Clin Cardiol. 1994;17:273. 23. Gussak I, Bjerregaard P, Egan TM, et al. ECG phenomenon

called the J wave. History, pathophysiology, and clinical signifi-cance. J Electrocardiogr. 1995;28:49.

24. Solomon A, Barish RA, Browne B, et al. The electrocardio-graphic features of hypothermia. J Emerg Med. 1989;7:169.

25. Braun R, Krishel S. Environmental emergencies. Emerg Med Clin North Am. 1997;15:451.

26. Lazar HL. The treatment of hypothermia. N Engl J Med. 1997;337:1545.

27. Bartley B, Crnkovich DJ, Usman AR, Carlson RW. Techniques for managing severe hypothermia. J Crit Illness. 1996;11:123.

28. Handrigan MT, Wright RO, Becker BM, et al. Factors and methodology in achieving ideal delivery temperatures for intravenous and lavage fluid in hypothermia. Am J Emerg Med. 1997;15:350.

29. Murphy K, Nowak RM, Tomlanovich MC. Use of bretylium tosylate as prophylaxis and treatment in hypothermic ven-tricular fibrillation in the canine model. Ann Emerg Med. 1986;15:1160.

30. Orts A, Alcaraz C, Delaney KA, et al. Bretylium tosylate and electrically induced cardiac arrhythmia during hypothermia in dogs. Am J Emerg Med. 1992;10:311.

31. Gentilello LM. Advances in the management of hypothermia. Surg Clin North Am. 1995;75:243.

32. Koller R, Schnider TW, Neidhart P. Deep accidental hypo-thermia and cardiac arrest—rewarming with forced air. Acta Anaesthesiol Scand. 1997;41:1359.

33. Kimberger O, Held C, Stadelmann K, et al. Resistive polymer versus forced-air rewarming: comparable heat transfer and core rewarming rates in volunteers. Anesth Analg. 2008;107:1621.

34. Fanelli A, Danelli G, Ghisi D, et al. The efficacy of a resistive heating under-patient blanket versus a forced-air warming sys-tem: a randomized controlled trial. Anesth Analg. 2009;108:199.

35. Steele MT, Nelson MJ, Sessler DI, et al. Forced air speeds rewarming in accidental hypothermia. Ann Emerg Med. 1996;27:479.

Section11-O-Ref.indd 1 12/10/2014 8:08:32 PM

References2

36. Lloyd ELI. Accidental hypothermia treated by central rewarm-ing through the airway. Br J Anaesth. 1973;45:41.

37. Slovis CM, Bachvarov HL. Heated inhalation treatment of hypothermia. Am J Emerg Med. 1984;2:533.

38. Giesbrecht GG, Bristow GK. Recent advances in hypothermia research. Ann NY Acad Sci. 1997;813:663.

39. Hall KN, Syverud SA. Closed thoracic cavity lavage in the treat-ment of severe hypothermia in human beings. Ann Emerg Med. 1990;19:204.

40. Iversen RJ, Atkin SH, Jaker MA, et al. Successful CPR in a severely hypothermic patient using continuous thoracostomy lavage. Ann Emerg Med. 1990;19:1335.

41. Winegard C. Successful treatment of severe hypothermia and prolonged cardiac arrest with closed thoracic cavity lavage. J Emeg Med. 1997;15:629.

42. Plaisier BR. Thoracic lavage in accidental hypothermia with cardiac arrest—a report of a case and review of the literature. Resuscitation. 2005;66:99.

43. Kristensen G, Gravesen H, Benveniste D, Jordening H. An oesphageal thermal tube for rewarming in hypothermia. Acta Anaesthesiol Scand. 1985;29:846.

44. Ledingham IM, Routh GS, Douglas IHS, MacDonald AM. Central rewarming system for treatment of hypothermia. Lancet. 1980;1:1168.

45. Hernandez E, Praga M, Alcazar JM, et al. Hemodialysis for treatment of accidental hypothermia. Nephron. 1993;63:214.

46. Brodersen HP, Meurer T, Bolzenius K, et al. Hemofiltration in severe hypothermia with favorable outcome. Clin Nephrol. 1996;45:413.

47. Gentilello LM, Cobean RA, Offner PJ, et al. Continuous arterio-venous rewarming: Rapid reversal of hypothermia in critically ill patients. J Trauma. 1992;32:316.

48. Tiruvoipati R, Balasubramanian SK, Khoshbin, E, et al. Successful use of extracorporeal membrane oxygenation in acci-dental hypothermic cardiac arrest. ASAIO Journal. 2005;51:474.

49. Ruttman E, Weissenbacher A, Ulmer H, et al. Prolonged extra-corporeal membrane oxygenation-assisted support provides

improved survival in hypothermic patients with cardiocircula-tory arrest. J Thorac Cardiovasc Surg. 2007;134:594.

50. Vretenas DF, Urschel JD, Parrott JCW, Unruh HW. Cardiopulmonary bypass resuscitation for accidental hypother-mia. Ann Thorac Surg. 1994;58:895.

51. Waters DJ, Belz M, Lawse D, Ulstad D. Portable cardiopulmo-nary bypass: resuscitation from prolonged ice-water submer-sion and asystole. Ann Thorac Surg. 1994;57:1018.

52. Gregory JS, Bergstein JM, Aprahamian C, et al. Comparison of three methods of rewarming from hypothermia: advantages of extracorporeal blood warming. J Trauma. 1991;31:1247.

53. Ireland AJ, Pathi VL, Crawforn R, Colquhoun IW. Back from the dead: extracorporeal rewarming of severe accidental hypo-thermia victims in accidental emergency. J Accid Emerg Med. 1997;14:255.

54. Walpoth BH, Walpoth-Aslan BN, Mattle HP, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood rewarming. N Engl J Med. 1997;337:1500.

55. Ban LH, Leone M, Blasco V, et al. A novel intravascular rewarm-ing method to treat severe hypothermia. Eur J Emerg Med. 2008;15:36.

56. Lanlewicz L, Lyn-Kew K, Silbergleit R. Rapid endovascu-lar warming for profound hypothermia. Ann Emerg Med. 2008;51:160.

57. Fildes J, Sheaff C, Barrett J. Very hot intravenous fluid in the treatment of hypothermia. J Trauma. 1993;35:683.

58. Sheaff CM, Fildes JJ, Keogh P, et al. Safety of 65°C intravenous fluid for the treatment of hypothermia. Am J Surg. 1996;172:52.

59. Mair P, Kornberger E, Furtwaengler W, et al. Prognostic mark-ers in patients with severe accidental hypothermia and cardio-circulatory arrest. Resuscitation. 1994;27:47.

60. Danzl DF, Hedges JR, Pozos RS, et al. Hypothermia out-come score: development and implications. Crit Care Med. 1989;17:227.

61. Schaller M-D, Fischer AP, Perret CH. Hyperkalemia: a prognostic factor during acute severe hypothermia. JAMA. 1990;264:1842.

Section11-O-Ref.indd 2 12/10/2014 8:08:32 PM

Chapter 132

REFERENCES

1. Pendergast DR, Lundgren CE. The underwater environment: cardiopulmonary, thermal, and energetic demands. J Appl Physiol. 2009;106:276-283.

2. Stolp BW, Lundgren CEG, Piantadosi CA. Diving and immersion. In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The Lung: Scientific Foundations. New York, NY: Raven Press; 1996:489.

3. Schatagay E. Diving Hyperb Med. 2011;41:216-228. 4. Naval Sea Systems Command, Supervisor of Diving US Navy:

U.S. Navy Diving Manual, Vols 1-5, 5th ed. Palm Beach Gardens, FL: Best Publishing; 2008.

5. Hamilton, RW, Thalmann ED: Decompression practice. In: Brubakk AO, Neuman TS, eds. Bennett & Elliott’s The Physiology and Medicine of Diving. 5th ed. Philadelphia, PA: WB Saunders; 2003:455-500.

6. Weathersby PK, Homer LD, Flynn ET. On the likelihood of decompression sickness. J Appl Physiol. 1984;57:815.

7. Lam TH, Yau KP. Manifestations and treatment of 793 cases of decompression sickness in a compressed air tunneling project in Hong Kong. Undersea Biomed Res. 1988;15:377.

8. Vann RD, Butler FK, Mitchell SJ, Moon RE. Decompression ill-ness. Lancet. 2011;377:153-164.

9. Hallenbeck JM, Bove AA, Elliott DH. Mechanism underlying spinal cord damage in decompression sickness. Neurology. 1975;25:308.

10. Leitch DR, Hallenback JM. Neurological forms of decompres-sion sickness. In: Shilling CW, Carlston CB, Mathias RA, eds. The Physician’s Guide to Diving Medicine. New York: Plenum Press; 1984:326.

11. Francis TJR, et al. Is there a role for the autochthonous bubble in the pathogenesis of spinal cord decompression sickness? Neuropathol Exp Neurol. 1988;47:475.

12. Moon RE, Camporesi EM, Kisslo JA. Patent foramen ovale and decompression sickness in divers. Lancet. 1989;1:513.

13. Cantais E, Louge P, Suppini A, et al. Right-to-left shunt and risk of decompression illness with cochleovestibular and cerebral symptoms in divers: case control study in 101 consecutive dive accidents. Crit Care Med. 2003;31:84.

14. Dahlback GO, Lundgren CEG. Pulmonary air-trapping induced by immersion. Aerospace Med. 1972;43:768.

15. Katz J, Leiman BC, Butler BD. Effects of inhalation anaesthetics on filtration of venous gas emboli by the pulmonary vascula-ture. Br J Anaesth. 1988;61:200.

16. Thalmann ED. Principles of U.S. Navy recompression treat-ments for decompression sickness. In: Moon RE, Sheffield PJ, eds. Treatment of Decompression Illness. 45th Workshop of the Undersea and Hyperbaric Medical Society. Kensington, Maryland: Undersea and Hyperbaric Medical Society; 1996:75.

17. Butler BD, Hills BA. The lung as a filter for microbubbles. J Appl Physiol. 1979;47:537.

18. Neuman TS, Spragg RG, Wagner PD, et al. Cardiopulmonary consequences of decompression stress. Respir Physiol. 1980;41:143.

19. Butler BD, Katz J. Vascular pressures and passage of gas emboli through the pulmonary circulation. Undersea Biomed Res. 1988;15:203.

20. Kutty S, Sengupta PP, Khandheria BK. Patent foramen ovale: the known and the to be known. J Am Coll Cardiol. 2012;59:1665-1671.

21. Bandi VD, Munnur U, Matthay MA. Acute lung injury and acute respiratory distress syndrome in pregnancy. Crit Care Clin. 2004;20:577-607.

22. Lamm WJE, Luchtel D, Albert RK. Sites of leakage in three models of acute lung injury. J Appl Physiol. 1988;64:1079.

23. Zwirewich CV, Muller NL, Abboud RT, et al. Noncardiogenic pulmonary edema caused by decompression sickness: rapid res-olution following hyperbaric therapy. Radiology. 1987;163:81.

24. Marini JJ, Culver BH. Systemic gas embolism complicating mechanical ventilation in the adult respiratory distress syn-drome. Ann Intern Med. 1989;110:699.

25. Hadjimiltiades S, Goldbaum TS, Mostel E, et al. Coronary air embolism during coronary angioplasty. Catheter Cardiovasc Diagn. 1989;16:164.

26. Kanter AS, Stewart BF, Hampson NB. Myocardial infarction during scuba diving: a case report and review. Am Heart J. 1995;130:1292.

27. Smith RM, Neuman TS. Elevation of serum creatine kinase in divers with arterial gas embolization. N Engl J Med. 1994;330:19.

28. Gottlieb JD, Ericsson JA, Sweet RB. Venous air embolism: a review. Anesth Analg. 1965;44:773.

29. Mehlhorn U, Burke EJ, Butler BD, et al. Body position does not affect hemodynamic response to venous air embolism in dogs. Anesth Analg. 1994;79:734.

30. Butler BD, Luehr S, Katz J. Venous gas embolism: time course of residual pulmonary intravascular bubbles. Undersea Biomed Res. 1989;16:21.

Section11-O-Ref.indd 1 12/10/2014 8:08:32 PM

References2

31. Dutka AJ. A review of pathophysiology and potential applica-tion of experimental therapies for cerebral ischemia to the treatment of cerebral arterial gas embolism. Undersea Biomed Res. 1985;12:403.

32. Moon RE. Treatment of diving emergencies. Crit Care Clin. 1999;15:429.

33. Moon RE, ed. Adjunctive Therapy for Decompression Illness. Report of the DCI Adjunctive Therapy Committee of the Undersea and Hyperbaric Medical Society. Kensington, Maryland: Undersea and Hyperbaric Medical Society; 2003.

34. Tetzlaff K, Shank ES, Muth CM. Evaluation and management of decompression illness-intensivist’s perspective. Intensive Care Med. 2003;29:2128.

35. Weaver LK. Hyperbaric oxygen in the critically ill. Crit Care Med. 2011;39:1784-1791.

36. Trytko BE, Bennett MH. Arterial gas embolism: a review of cases at Prince of Wales Hospital, Sydney, 1996 to 2006. Anaesth Intensive Care. 2008;36:60-64.

37. Bitterman H, Melamed Y. Delayed hyperbaric treatment of cerebral air embolism. Isr J Med Sci. 1993;29:22.

38. Papa L, Hoelle, R, Idris A. Systematic review of definitions for drowning incidents. Resuscitation. 2005;65:255-264.

39. Shaw KN, Briede CA. Submersion injuries: drowning and near-drowning. Emerg Med Clin North Am. 1989;7:355.

40. Modell JH. Drowning. N Engl J Med. 1993;328:253. 41. Layon AJ, Modell JH. Drowning: update 2009. Anesthesiology.

2009;110:1390-1401. 42. Soar J, Perkins GD, Abbas G, et al. European Resuscitation

Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, elec-trocution. Resuscitation. 2010;81:1400-1433.

43. Colebatch HJH, Halmagyi DFJ. Lung mechanics and resuscita-tion after fluid aspiration. J Appl Physiol. 1961;16:684.

44. Lheureux P, Vincent JL, Brimioulle S. Fulminant pulmonary edema after near-drowning: remarkably high colloid osmotic pressure in tracheal fluid. Intensive Care Med. 1984;10:205.

45. Kaukinen L. Clinical course and prognostic signs in near drowning patients. Ann Chir Gynaecol. 1984;73:34.

46. Oakes DD, Sherck JP, Maloney JR, et al. Prognosis and manage-ment of victims of near-drowning. J Trauma. 1982;22:544.

47. Staworn D, Lewison L, Marks J, et al. Brain death in pediatric intensive care unit patients: incidence, primary diagnosis, and the clinical occurrence of Turner’s triad. Crit Care Med. 1994;22:1301.

48. Nolan JP, Soar J, Zideman DA, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation. 2010;81:1219-1276.

49. Siebke H, Breivik H, Rod T, et al. Survival after 40 minutes’ submersion without cerebral sequelae. Lancet. 1975;1:1275.

50. Modell JH, Graves SA, Kuck EJ. Near-drowning: correla-tion of level of consciousness and survival. Can Anaesth Soc. 1980;27:211.

51. Conn AW, Montes JE, Barker GA, et al. Cerebral salvage in near-drowning following neurological classification by triage. Can Anaesth Soc J. 1980;27:201.

52. Sarnaik AP, Vohra MP. Near-drowning: fresh, salt, and cold water immersion. Clin Sports Med. 1986;5:33.

53. Modell JH, Graves SA, Ketover A. Clinical course of 91 con-secutive near-drowning victims. Chest. 1976;70:231.

54. Yagil Y, Stalnikowicz R, Michaeli J, et al. Near drowning in the Dead Sea. Arch Intern Med. 1985;145:50.

55. Karch SB. Pathology of the heart in drowning. Arch Pathol Lab Med. 1985;109:176.

56. Doroshow RW, Ashwal S, Saukel GW. Availability and selec-tion of donors for pediatric heart transplantation. J Heart Lung Transplant. 1995;14:52.

57. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund CM, Ackerman MJ. Spectrum and frequency of cardiac chan-nel defects in swimming-triggered arrhythmia syndromes. Circulation. 2004;110:2119-2124.

58. Tester DJ, Medeiros-Domingo A, Will ML, Ackerman MJ. Unexplained drownings and the cardiac channelopathies: a molecular autopsy series. Mayo Clin Proc. 2011;86:941-947.

59. Neale TJ, Dewar JM, Parr R, et al. Acute renal failure following near drowning in salt water. NZ Med J. 1984;97:319.

60. Ports TA, Deuel TF. Intravascular coagulation in fresh-water submersion. Ann Intern Med. 1977;87:60.

61. Agar JWM. Rhabdomyolysis and acute renal failure after near-drowning in cold salt water. Med J Aust. 1994;161:686.

62. Manolios N, Mackie I. Drowning and near-drowning on Australian beaches patrolled by life-savers: a 10-year study, 1973–1983. Med J Aust. 1988;148:165.

63. Butler T, Shin S, Collins J, Britt RC, et al. Cervical spinal cord injury associated with near-drowning does not increase pneu-monia risk or mortality. Am Surg. 2011;77:426-429.

64. Sims JK, Enomoto PI, Frankel RI, et al. Marine bacteria compli-cating seawater near-drowning and marine wounds: a hypoth-esis. Ann Emerg Med. 1983;12:212.

65. Modell JH, Davis JH, Giammona ST, et al. Blood gas and electrolyte changes in human near-drowning victims. JAMA. 1968;203:99.

66. Fromm RE. Hypercalcemia complicating an industrial near-drowning. Ann Emerg Med. 1991;20:669.

67. Boles JM, Mabille S, Scheydecker JL, et al. Hypoglycemia in salt water near-drowning victims. Correspondence. Intensive Care Med. 1988;14:30.

68. Perez-Benavides F, Riff E, Franks C. Adult respiratory distress syndrome and artificial surfactant replacement in the pediatric patient. Pediatr Emerg Care. 1995;11:153.

69. Wenger JD, Hollis DG, Weaver RE, et al. Infection caused by Francisella philomiragia (formerly Yersinia philomiragia). Ann Intern Med. 1989;110:888.

70. Bohn DJ, Biggar WD, Smith CR, et al. Influence of hypother-mia, barbiturate therapy, and intracranial pressure monitoring on morbidity and mortality after near-drowning. Crit Care Med. 1986;14:529.

71. Anonymous: Advanced challenges in resuscitation. Submersion or near drowning. Resuscitation. 2000;46:273.

72. Lavelle JM, Shaw KN. Near drowning: Is emergency department cardiopulmonary resuscitation or intensive care unit cerebral resuscitation indicated? Crit Care Med. 1993;21:368.

Section11-O-Ref.indd 2 12/10/2014 8:08:32 PM

References 3

73. Modell JH. Treatment of near-drowning: is there a role for H.Y.P.E.R. therapy? Crit Care Med. 1986;14:593.

74. Connors R, Frewen TC, Kissoon N, et al. Relationship of cross-brain oxygen content difference, cerebral blood flow, and meta-bolic rate to neurologic outcome after near-drowning. J Pediatr. 1992;121:839.

75. Schwartz BG, Kloner RA, Thomas JL, et al. Therapeutic hypo-thermia for acute myocardial infarction and cardiac arrest. Am J Cardiol. April 27, 2012;110:461-466.

76. Choi HA, Badjatia N, Mayer SA. Hypothermia for acute brain injury-mechanisms and practical aspects. Nat Rev Neurol. 2012;8:214-222.

77. Choi SP, Youn CS, Park KN, et al. Therapeutic hypothermia in adult cardiac arrest because of drowning. Acta Anaesthesiol Scand. 2012;56:116-123.

78. Bratton SL, Jardine DS, Morray JP. Serial neurologic examina-tions after near drowning and outcome. Arch Pediatr Adolesc Med. 1994;148:167.

Section11-O-Ref.indd 3 12/10/2014 8:08:32 PM